<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":6021,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Momenta Pharm., Inc. v. Amphastar Pharm., Inc., 686 F.3d 1348, 103 U.S.P.Q.2d 1800 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/9aca369ec3d150f388aba63c52579ed6'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/9aca369ec3d150f388aba63c52579ed6'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1CCU8ON?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1CCU8ON">Previous Result: <span>Central New York Laborers&#x27; Health &amp; Welf...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1I2EGU003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I2EGU003">Next Result: <span>United States v. Alcatel-Lucent France, ...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation distinguished" title="Distinguished"></div>
<div class='title left' title='Momenta Pharm., Inc. v. Amphastar Pharm., Inc., 686 F.3d 1348, 103 U.S.P.Q.2d 1800 (Fed. Cir. 2012), Court Opinion'>
Momenta Pharm., Inc. v. Amphastar Pharm., Inc., 686 F.3d 1348, 103 U.S.P.Q.2d 1800 (Fed. Cir....
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Momenta Pharm., Inc. v. Amphastar Pharm., Inc., 686 F.3d 1348, 103 U.S.P.Q.2d 1800 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1I2EH8003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Momenta Pharm., Inc. v. Amphastar Pharm., Inc.</div>
<div class='displayCitation'>103 U.S.P.Q.2d 1800</div>
<div class='displayCitation'>2012 BL 196196</div>
<div class='displayCitation'>686 F.3d 1348</div>
<div class='displayCitation'>bna a0d3x9x0a1</div>
<div class='displayCitation'>bna a0d4f8f0v2</div>
<div class='displayCitation'>wkffecase:26254612</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1I2EH8003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Momenta Pharm., Inc. v. Amphastar Pharm., Inc., 686 F.3d 1348, 103 U.S.P.Q.2d 1800 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Momenta Pharm., Inc. v. Amphastar Pharm., Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1I2EH8003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1I2EH8003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1I2EH8003" /><input id="title" name="title" type="hidden" value="Momenta Pharm., Inc. v. Amphastar Pharm., Inc., 686 F.3d 1348, 103 U.S.P.Q.2d 1800 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="DISTINGUISHED" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="9aca369ec3d150f388aba63c52579ed6" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1I2EH8003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%39aca%33%36%39ec%33d%31%35%30f%33%38%38aba%36%33c%35%32%35%37%39ed%36%2Fdocument%2FX%31I%32EH%38%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/bcite/X1I2EH8003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/bcite/X1I2EH8003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/bcite/X1I2EH8003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/related_content/X1I2EH8003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1720622252035";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">686 F.3d 1348</div>
<div class="cite" data-cite-type="ReporterOfDecisions">103 U.S.P.Q.2d 1800</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 2012-1062, 2012-1103, 2012-1104.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 196196</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
MOMENTA PHARMACEUTICALS, INC., Plaintiff-Appellee, and Sandoz, Inc.,
Plaintiff-Appellee v. AMPHASTAR PHARMACEUTICALS, INC., International
Medication Systems, Ltd., Watson Pharmaceuticals, Inc., and Watson Pharma.,
Inc., Defendants-Appellants.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 2012-1062, 2012-1103, 2012-1104.
</center></p>
<p><center>
August 3, 2012.
<span CLASS="page_no" data-cite="103 uspq 2d 1802" data-cite-type="ReporterOfDecisions" data-cite-pageno="1802" data-primary-citation="103 U.S.P.Q.2d 1800">[**1802]</span> </center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_925351" href="#headnote_ref_pq2-dec_925351">[1]</a> <span>Infringement &mdash; Defenses &mdash; Regulatory compliance </span> <a href="http://www.bloomberglaw.com/document/1720622252035/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1113" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1113">&#9658;120.1113</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnote_text">
&ldquo;Safe harbor&rdquo; provision of 35 U.S.C. &sect;271(e)(1), which states that it is not act of infringement to make, use, or sell patented invention solely for uses &ldquo;reasonably related&rdquo;
to developing and submitting information pursuant to &ldquo;a federal law&rdquo; regulating manufacture, use or sale of drugs, is not limited to submission of information pursuant to abbreviated new drug application provisions of Federal Food, Drug, and Cosmetic Act, since Section 271(e)(1) does not reference 21 U.S.C. &sect;355(j), which describes ANDA requirements, and broad language of safe harbor instead unambiguously applies to submissions under any federal law, provided that law &ldquo;regulates the manufacture, use, or sale of drugs,&rdquo; and since this interpretation is consistent with remainder of statutory scheme, in that, unlike closely related infringement provision, 35 U.S.C. &sect;271(e)(2), safe harbor provision is not linked to submission of application under FDCA; phrase &ldquo;reasonably related&rdquo; does not mean that use of patented invention must necessarily result in submission of information to U.S. Food and Drug Administration, and as long as accused infringer has reasonable basis for believing that use of invention might yield information appropriate for inclusion in submission to FDA, its use meets &ldquo;reasonably related&rdquo; requirement. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_925352" href="#headnote_ref_pq2-dec_925352">[2]</a> <span>Infringement &mdash; Defenses &mdash; Regulatory compliance </span> <a href="http://www.bloomberglaw.com/document/1720622252035/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1113" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1113">&#9658;120.1113</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Records of defendants' allegedly infringing quality control testing of batches of generic drug were &ldquo;submitted&rdquo;
to U.S. Food and Drug Administration within meaning of &ldquo;safe harbor&rdquo; provision of 35 U.S.C. &sect;271(e)(1), which states that it is not act of infringement to make, use, or sell patented invention solely for uses &ldquo;reasonably related&rdquo; to &ldquo;development and submission&rdquo; of information pursuant to &ldquo;a Federal law&rdquo; regulating manufacture, use or sale of drugs, since defendants, as generic manufacturers under abbreviated new drug application, must comply with FDA regulations requiring that all records associated with produced batch of drugs be retained for at least one year after expiration date of batch, and that such records be &ldquo;readily available for authorized inspection&rdquo; by FDA at any time, since it is undisputed that records in question were produced in order to develop and submit to FDA proof that defendants' products comply with federal law, and since fact that FDA does not, in most cases, actually inspect records does not mean that records are not for &ldquo;development and submission of information under a Federal law.&rdquo;</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_925353" href="#headnote_ref_pq2-dec_925353">[3]</a> <span>Infringement &mdash; Defenses &mdash; Regulatory compliance </span> <a href="http://www.bloomberglaw.com/document/1720622252035/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1113" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1113">&#9658;120.1113</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnote_text">
Defendants' allegedly infringing quality control testing of batches of generic drug falls within scope of &ldquo;safe harbor&rdquo; provision of 35 U.S.C. &sect;271(e)(1), which states that it is not act of infringement to make, use, or sell patented invention solely for uses &ldquo;reasonably related&rdquo; to &ldquo;development and submission&rdquo; of information pursuant to &ldquo;a Federal law&rdquo; regulating manufacture, use or sale of drugs, even though scope of safe harbor provision does not extend to &ldquo;information that may be routinely reported to the [U.S. Food and Drug Administration], long after marketing approval has been obtained,&rdquo; since FDA regulations require defendants to conduct quality control testing and maintain batch testing records for inspection by FDA, and defendants'
submissions to FDA thus are not &ldquo;routine,&rdquo; in that information generated by testing is necessary both to continued approval of defendants'
abbreviated new drug application, and defendants' ability to market generic drug.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_925354" href="#headnote_ref_pq2-dec_925354">[4]</a> <span>Patent grant&mdash; Patent term extension; restoration </span> <a href="http://www.bloomberglaw.com/document/1720622252035/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=105.17" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="105.17">&#9658;105.17</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Infringement &mdash; Defenses &mdash; Regulatory compliance </span> <a href="http://www.bloomberglaw.com/document/1720622252035/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1113" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1113">&#9658;120.1113</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnote_text">
Application of &ldquo;safe harbor&rdquo; provision of 35 U.S.C. &sect;271(e)(1), which states that it is not act of infringement to make, use, or sell patented invention solely for uses &ldquo;reasonably related&rdquo; to &ldquo;development and submission&rdquo; of information pursuant to &ldquo;a Federal law&rdquo; regulating manufacture, use or sale of drugs, is not limited to activities carried out before U.S. Food and Drug Administration approves drug for manufacture and sale, and post-approval studies that meet requirements of statute therefore fall within scope of safe harbor; in present case, defendants'
allegedly infringing quality control testing of batches of generic drug falls within scope of safe harbor provision, even though defendants'
abbreviated new drug application has been approved, and noninfringing testing alternatives are allegedly available, since it is undisputed that defendants' tests are conducted to satisfy FDA's requirements, since safe harbor provision does not require use of noninfringing alternatives, but even if statute could be construed to mean that patented invention must be &ldquo;sole&rdquo; means of providing information, defendants herein are required, by FDA regulations, to use patented testing method to ensure that their generic drug is not &ldquo;adulterated,&rdquo;
and since availability of safe harbor is not limited to situations in which patent term extension is also available.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">REMEDIES</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_925355" href="#headnote_ref_pq2-dec_925355">[5]</a> <span>Non-monetary and injunctive &mdash; Equitable relief &mdash;
Preliminary injunctions &mdash; Patents </span> <a href="http://www.bloomberglaw.com/document/1720622252035/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=505.0707.07" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="505.0707.07">&#9658;505.0707.07</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnote_text">
Grant of preliminary injunction is vacated and remanded in action alleging that defendants' quality control testing of batches of their generic drug infringes patent in suit, since &ldquo;safe harbor&rdquo; provision of 35 U.S.C. &sect;271(e)(1) states that it is not act of infringement to make, use, or sell patented invention solely for uses &ldquo;reasonably related&rdquo; to &ldquo;development and submission&rdquo; of information pursuant to &ldquo;a Federal law&rdquo; regulating manufacture, use or sale of drugs, and plaintiffs'
admission that defendants' testing is carried out &ldquo;to satisfy the FDA's requirements&rdquo; therefore makes it unlikely that plaintiffs will succeed on merits of infringement claim, and since federal district court's findings regarding irreparable harm, balance of hardships, and public interest were all predicated, to some extent, on erroneous conclusion that plaintiffs' patent was infringed by defendants' product.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the District of
Massachusetts, Nathaniel M. Gorton, J.
</p></div>
<span CLASS="page_no" data-cite="686 f 3d 1349" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1349" data-primary-citation="686 F.3d 1348">[*1349]</span> <div id="para2" printdualcolumn="true"><p>
Robert S. Frank, Jr., Choate Hall &amp; Stewart LLP, of Boston, MA, argued for
both plaintiffs-appellees. With him on the brief was Eric J. Marandett. Of
counsel on the brief for plaintiff-appellee for Sandoz, Inc., was Thomas P.
Steindler, McDermott, Will &amp; Emery LLP, of Washington, DC.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Patricia A. Millett, Akin Gump Strauss Hauer &amp; Feld LLP, of Washington, DC,
argued for plaintiffs-appellants. With her on the brief were Anthony T.
Pierce, Mark Mansoiu;, Emily C. Johnson and James E. Tysse; and L. Rachel
Lerman, of Los Angeles, CA.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before RADER, Chief Judge, DYK and MOORE, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
MOORE, Circuit Judge.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Opinion for the court filed by Circuit Judge MOORE. Dissenting opinion
filed by Chief Judge RADER.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Amphastar Pharmaceuticals, Inc., International Medication Systems, Ltd.,
Watson Pharmaceuticals, Inc., and Watson Pharma., Inc. (collectively,
Amphastar) appeal the district court's order denying the Emergency Motion to
Dissolve or Stay the preliminary injunction entered in this case. Because
the district court applied an* unduly narrow interpretation of the
Hatch-Waxman safe harbor, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1), we vacate the grant of a
preliminary injunction and remand for further proceedings consistent with
this opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This case is a patent litigation involving a generic version of Lovenox
(enoxaparin), a drug that prevents blood clots. Enoxaparin is a low
molecular weight version of heparin, a naturally occurring molecule. Heparin
is a polymer, known as a polysaccharide, made up of long chains of sugar
molecules. Heparin is not a single defined molecule. Instead, heparin
molecules have considerable diversity in (1) the length of the
polysaccharide chain and (2) in the component disaccharide units and the
corresponding distribution of disaccharide unit sequences in the
polysaccharide chains. FDA Letter to Aventis Pharmaceuticals, Inc., July 23,
2010, FDA Docket <cite>No. FDA-2003-P-0273</cite> (FDA Letter), J.A. 291.
<span CLASS="page_no" data-cite="686 f 3d 1350" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1350" data-primary-citation="686 F.3d 1348">[*1350]</span> 
For example, the molecular weight of heparin molecules varies between 5,000
and 40,000 daltons. <i><cite>Id</cite>.</i> Likewise, the disaccharide units can vary between
two different uronic acid components, and each of four positions on the
disaccharide unit can be modified. <i><cite>Id</cite>.</i>, J.A. 291-92. The natural diversity
inherent to heparin stems from the biosynthetic pathway used to produce the
molecule. <i><cite>Id</cite>.</i>, J.A. 292. .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Enoxaparin is produced by breaking the heparin polysaccharide into smaller
pieces, called oligosaccharides. Because the heparin starting material is a
diverse set of molecules, enoxaparin is also made up of different chain
lengths and disaccharide units corresponding to the diversity in the
original mix <span CLASS="page_no" data-cite="2012 bl 196196 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> of heparin molecules. <i><cite>Id</cite>.</i> Additional diversity is introduced
based on the way in which the heparin molecule is broken down into the low
molecular weight heparin product. <i><cite>Id</cite>.</i>, JA 292-93. Thus, unlike a typical
small molecule drug like penicillin, enoxaparin is made up of a range of
different molecules.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This molecular diversity raises a potential problem in light of the Food
and Drug Administration's (FDA's) abbreviated new drug application (ANDA)
approval process. ANDAs are typically used by generic companies to obtain
approval to market a generic version of an existing drug. Unlike a new drug
application (NDA), an ANDA applicant is not required to submit the same
extensive clinical studies typically needed to prove the drug's safety and
efficacy. Instead, the ANDA applicant must submit studies to establish that
its drug is bio-equivalent to the reference drug. The <span CLASS="page_no" data-cite="103 uspq 2d 1803" data-cite-type="ReporterOfDecisions" data-cite-pageno="1803" data-primary-citation="103 U.S.P.Q.2d 1800">[**1803]</span> ANDA must also include
sufficient information to establish that the generic drug has the same
active ingredients as the reference drug.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The obvious complication with using an ANDA application to gain approval
for enoxaparin is that it is a mixture of a number of different low
molecular weight heparin molecules. In fact, Aventis, which marketed
Lovenox, asked the FDA to deny approval for a generic version of enoxaparin
via an ANDA unless the applicant either (1) completely characterized
enoxaparin by isolating, purifying, and sequencing each of its unique
polysaccharide chains, which Aventis claimed was impossible; (2) used
Aventis's manufacturing process; or (3) conducted clinical trials to prove
safety and efficacy (the very type of duplicative studies the ANDA approval
process was designed to avoid). FDA Letter, J.A. 286. The FDA rejected
Aventis's arguments, and instead explained that the ANDA "statutory
provisions do not describe the type or amount of information that an ANDA
applicant must submit to demonstrate that the active ingredient in the
generic drug product is the same as the active ingredient in the [reference
drug]." <i><cite>Id</cite>.</i>, J.A. 294. As a result, the FDA concluded that Congress
recognized that the FDA has "broad discretion with respect to the
information [it] may consider in making a finding on the `sameness' of an
active ingredient." <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Consistent with this discretion, the FDA identified five criteria, or
"standards for identity," that "together provide sufficient information to
conclude that generic enoxaparin has the `same' active ingredient as
Lovenox." <i><cite>Id</cite>.</i>, J.A. 295. These criteria included, <i>inter alia</i>, "[e]quivalence
in disaccharide building blocks, fragment mapping, and sequence of
oligosaccharide species." <i><cite>Id</cite>.</i> The FDA explained that such equivalence is
proven by "exhaustive digestion of enoxaparin with purified heparin
digesting enzymes (heparinases I, II, III) and nitrous acid, among other
means, to yield the constituent disaccharide building blocks comprising
enoxaparin." <i><cite>Id</cite>.</i>, J.A. 300.
<span CLASS="page_no" data-cite="686 f 3d 1351" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1351" data-primary-citation="686 F.3d 1348">[*1351]</span> 
These disaccharides can then potentially be "separated and quantified" by a
number of techniques, including capillary electrophoresis (CE), reverse
phase high <span CLASS="page_no" data-cite="2012 bl 196196 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> performance liquid chromatography (RPHPLC), and strong anion
exchange high performance liquid chromatography (SAXHPLC). <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA also suggested the identity of the disaccharides could be
determined via standard techniques, including mass spectroscopy, NMR
spectroscopy, modifying reagents, or modifying enzymes. These techniques
identify the nature of the constituent sugars and their substitution
patterns, including the sulfation and acetylation patterns, as well as
"whether the disaccharide possesses, among other structures, a . . . 1, 6
anhydro ring" structure. <i><cite>Id</cite>.</i>, J.A. 300-01. Detecting the presence of a 1, 6
anhydro ring structure is particularly important for proving equivalence
because "[e]quivalence in disaccharide building blocks together with
equivalence . in molecular weight distribution shows that generic enoxaparin
contains the 1, 6 anhydro ring structure at the reducing ends of between 15
percent and 25 percent of its poly(oligo)saccharide chains." <i><cite>Id</cite>.</i> n. 68, J.A.
301.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Amphastar was the first company to file an ANDA for a generic version of
enoxaparin. It submitted its ANDA to the FDA in March 2003, and subsequently
engaged in a lengthy patent litigation with Sanofi-Aventis. Amphastar
received FDA approval to market its generic enoxaparin on September 19,
2011. Despite the fact that Amphastar was the first company to file an ANDA,
Momenta Pharmaceuticals, Inc. and Sandoz, Inc. (collectively Momenta), who
collaborated to develop a generic enoxaparin product, were the first to
bring generic enoxaparin to the marketplace. Momenta received FDA approval
to market enoxaparin in July 2010, more than a year before Amphastar's
approval. Being the only generic version of enoxaparin has it benefits: its
sales generated revenues of $260 million <i>per quarter.</i> J.A. 189. The approval
of Amphastar's version of enoxaparin, and the resultant ruinous competition
of another generic version of the drug, threatened this unique market
position. Understandably unwilling to give up a billion dollars in yearly
revenue, Momenta initiated the present litigation two days after Amphastar
received final FDA approval to market its generic enoxaparin.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Momenta is the assignee of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X3H8SA841GJ?jcsearch=usp%207575886&amp;summary=yes#jcite">United States Patent No. 7,575,886</a> ('886
patent). The '886 patent generally relates "to methods for analyzing
heterogeneous populations of sulfated polysaccharides, e.g. heparin [and] .
. . LMWH [e.g., enoxaparin.]" '886 patent col.4 11.53-55. Claim 6 is
typical. It is a method for analyzing an enoxaparin sample "for the presence
or amount of a non naturally occurring sugar . . . that results from a
method of making enoxaparin <span CLASS="page_no" data-cite="103 uspq 2d 1804" data-cite-type="ReporterOfDecisions" data-cite-pageno="1804" data-primary-citation="103 U.S.P.Q.2d 1800">[**1804]</span> that included peliminative cleavage with a
benzyl ester and depolymerization." <i>Id.</i> col.64 11.35-39. Momenta also
asserted independent claims 15, which assesses the level of non-naturally
occurring sugar, and 53, which allows selection of an appropriate batch.
These claims are similar to claim 6. The asserted claims generally require
digestion of an enoxaparin sample with a heparin degrading enzyme, followed
by the use of a separation method to detect the <span CLASS="page_no" data-cite="2012 bl 196196 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> presence of the
non-naturally occurring sugar resulting from the B-eliminative cleavage. The
signal corresponding to the non-naturally occurring sugar can then be used
to analyze the test sample based on a comparison with a reference standard.
<i>Id.</i> col.64 11.40-57.
<span CLASS="page_no" data-cite="686 f 3d 1352" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1352" data-primary-citation="686 F.3d 1348">[*1352]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Momenta alleged that Amphastar infringed the '886 patent by "manufacturing
generic enoxaparin for commercial sale" using the claimed methods. J.A. 58.
Momenta asserted that Amphastar "included in their process for manufacturing
batches of enoxaparin sodium. . . . a method for determining that a defined
percentage of the oligosaccharide chains that make up enoxaparin include . .
. a non-naturally occurring sugar that includes a 1, 6-anhydro ring
structure, which method infringes the '886 patent." J.A. 57. Momenta also
alleged that this infringing testing was necessary because the "FDA requires
a generic manufacture to include in its manufacturing process the analysis
of each batch of its enoxaparin drug substance to confirm that . . . [it]
includes a 1, 6-anhydro ring structure." J.A. 56. Momenta moved for and
received a temporary restraining order to prevent the irreparable harm of
additional generic entry from Amphastar. J.A. 4. The district court
subsequently granted Momenta a preliminary injunction based on its belief
that Amphastar's quality control batch testing infringed the '886 patent.
J.A. 30. Amphastar later filed two emergency motions for relief from the
preliminary injunction, which the district court denied.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Amphastar sequentially appealed the preliminary injunction and the two
denials for relief from the preliminary injunction. These three appeals were
consolidated. We have jurisdiction to hear these appeals pursuant to
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEIMUA003?jcsearch=28%20usc%201292&amp;summary=yes#jcite">28 U.S.C. &sect; 1292</a>. After hearing oral argument in this case, we stayed the
preliminary injunction. This stay, however, was not a final decision on the
merits of Amphastar's appeal. We now explain why the district court
incorrectly concluded that Momenta was likely to succeed on the merits of
its infringement claim, and conclude that the preliminary injunction must be
vacated.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  ANALYSIS
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "The issuance of a preliminary injunction . . . is a matter of discretion
for a district court. That discretion, however, is not absolute and must be
reviewed in light of the equitable standards governing the issuance of
injunctions." <i>Intel Corp. v. ULSI Sys. Tech., Inc.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X4APIK?jcsearch=995%20f%202d%201566&amp;summary=yes#jcite">995 F.2d 1566</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X4APIK?jcsearch=995%20f%202d%201566&amp;summary=yes#jcite">1568</a>
(Fed.Cir.1993). To determine whether a preliminary injunction is
appropriate, the district court weighs factors including "(1) whether the
movant has sufficiently established a reasonable likelihood of success on
the merits; (2) whether the movant would suffer irreparable harm if the
injunction were not granted; (3) whether the balance of hardships tips in
the movant's favor; and (4) the impact, if any, of the injunction on the
public interest." <i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X4APIK?jcsearch=995%20F.2d%201566&amp;summary=yes#jcite">Id</a>.</i> The grant of a preliminary injunction can be
overturned "by showing that the court made a clear error of judgment in
weighing relevant factors or exercised its discretion based upon an error of
law or clearly erroneous factual findings." <i>Genentech, Inc. v. Novo</i>
<i>NordiskA/S</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X4K9GE?jcsearch=108%20f%203d%201361&amp;summary=yes#jcite">108 F.3d 1361</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X4K9GE?jcsearch=108%20f%203d%201361&amp;summary=yes#jcite">1364</a> (<span CLASS="page_no" data-cite="2012 bl 196196 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> Fed.Cir.1997). As the party seeking the
injunction, the burden is on Momenta to establish it is entitled to this
extraordinary relief. <i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X4K9GE?jcsearch=108%20F.3d%201361&amp;summary=yes#jcite">Id</a>.</i> In order to prove a likelihood of success on the
merits, Momenta must prove that Amphastar likely infringes its patent. <i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X4K9GE?jcsearch=108%20F.3d%201361&amp;summary=yes#jcite">Id</a>.</i>
Conversely, if Amphastar establishes that Momenta is unlikely to succeed on
its claim of infringement, a preliminary injunction is likely not
appropriate. <i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X4K9GE?jcsearch=108%20F.3d%201361&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In its opposition to the preliminary injunction, Amphastar argued, among
other things, that its testing falls within the scope of the Hatch-Waxman
safe harbor, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1). <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">Section 271(e)(1)</a> indicates that "[i]t
shall not be an act of infringement to . . . use . . . a patented
<span CLASS="page_no" data-cite="686 f 3d 1353" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1353" data-primary-citation="686 F.3d 1348">[*1353]</span> 
invention . . . solely for uses reasonably related to the development and
submission of information under a Federal law which regulates the
manufacture, use, or sale of drugs. . . ." The district court found that
"the alleged infringing activity involves the use of plaintiffs' patented
quality control' testing methods on each commercial batch of enoxaparin that
will be sold after FDA approval." <span CLASS="page_no" data-cite="103 uspq 2d 1805" data-cite-type="ReporterOfDecisions" data-cite-pageno="1805" data-primary-citation="103 U.S.P.Q.2d 1800">[**1805]</span> J.A. 31; <i>see also</i> J.A. 56 (Momenta's
complaint alleging that the "FDA requires" the testing). While acknowledging
that Amphastar's use of the patented method was for the purpose of
developing information to submit to the FDA, the district court nevertheless
concluded that the safe harbor does not apply to Amphastar's testing:
"although the safe harbor provision permits otherwise infringing activity
that is conducted to obtain regulatory approval of a product, it does not
permit a generic manufacturer to continue in that otherwise infringing
activity after obtaining such approval." J.A. 23. In reaching this
conclusion, the district court focused primarily on the legislative history
of the safe harbor, as quoted in one of our prior cases, <i>Classen</i>
<i>Immunotherapies, Inc. v. Biogen IDEC</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20f%203d%201057&amp;summary=yes#jcite">659 F.3d 1057</a> (Fed. Cir.2011). J.A.
23.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, Amphastar argues that the district court took an unduly
restrictive view of the safe harbor, and that its activities fall within the
plain language of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1). Momenta counters that the district
court correctly held that the safe harbor does not apply to Amphastar's
testing for two reasons. First, Momenta argues that the safe harbor does-not
apply to post-approval activity: "In <i>Classen</i>, this court squarely held that
`[t]he [safe harbor] does not apply to information that may be routinely
reported to the FDA long after marketing approval has been obtained.'"
Appellee's Br. at 43 (quoting <i>Classen</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20f%203d%201057&amp;summary=yes#jcite">659 F.3d at 1070</a>, alterations made by
Momenta). Because Amphastar's batch testing is carried out as a condition
for the post-FDA approval sale of enoxaparin, Momenta argues it falls
outside the scope of the safe harbor.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, despite its allegations and concessions, Momenta asserts the safe
harbor does not apply because "the FDA does not require the use of the
particular procedure that is claimed in the '<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X3H8SA841GJ?jcsearch=usp%207575886&amp;summary=yes#jcite">886 patent</a>." <i></i><cite>Id. at 41</cite>.
Instead, Momenta claims that the FDA's interpretation of its statutory
mandate in its letter response to Aventis's petition, J.A. 300-01, allows a
variety of testing methods to be used to establish <span CLASS="page_no" data-cite="2012 bl 196196 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> equivalence, both for the
submission of an ANDA and for the undisputedly required batch testing.
Appellee's Br. at 41. Momenta argues that the availability of other
acceptable testing methods means that Amphastar's alleged use of the
patented method is not required by the FDA, and is therefore outside of the
safe harbor provision.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The parties thus present us with conflicting views about the scope of the
safe harbor. If Amphastar is correct that its post-approval activities
actually fall within the scope of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1), Momenta is unlikely
to succeed on its claim of infringement and the preliminary injunction is
likely inappropriate. <i>Genentech</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X4K9GE?jcsearch=108%20f%203d%201361&amp;summary=yes#jcite">108 F.3d at 1364</a>. In order to determine
whether the preliminary injunction was appropriate in this case; we must
first ascertain the scope of the Hatch-Waxman safe harbor provision,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "[A]ll statutory construction cases . . . begin with the language of the
statute." <i>Barnhart v. Sigmon Coal Co.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XAU34F?jcsearch=534%20us%20438&amp;summary=yes#jcite">534 U.S. 438</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XAU34F?jcsearch=534%20us%20438&amp;summary=yes#jcite">450</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XAU34F?jcsearch=122%20supreme%20court%20941&amp;summary=yes#jcite">122 S.Ct. 941</a>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XAU34F?jcsearch=151%20l%20ed%202d%20908&amp;summary=yes#jcite">151 L.Ed.2d 908</a> (2002).
<span CLASS="page_no" data-cite="686 f 3d 1354" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1354" data-primary-citation="686 F.3d 1348">[*1354]</span> 
The "first step in interpreting a statute is to determine whether the
language at issue has a plain and unambiguous meaning with regard to the
particular dispute in the case." <i>Robinson v. Shell Oil Co.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CCSA?jcsearch=519%20us%20337&amp;summary=yes#jcite">519 U.S. 337</a>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CCSA?jcsearch=519%20us%20337&amp;summary=yes#jcite">340</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CCSA?jcsearch=117%20supreme%20court%20843&amp;summary=yes#jcite">117 S.Ct. 843</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CCSA?jcsearch=136%20l%20ed%202d%20808&amp;summary=yes#jcite">136 L.Ed.2d 808</a> (1997). If the language of the statute
is unambiguous, there is no second step: "Our inquiry must cease if the
statutory language is unambiguous and `the statutory scheme is coherent and
consistent.'" <i>Id.</i> (quoting <i>United States v. Ron Pair Enters., Inc.</i>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBMT?jcsearch=489%20us%20235&amp;summary=yes#jcite">489 U.S. 235</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBMT?jcsearch=489%20us%20235&amp;summary=yes#jcite">240</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBMT?jcsearch=109%20supreme%20court%201026&amp;summary=yes#jcite">109 S.Ct. 1026</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBMT?jcsearch=103%20l%20ed%202d%20290&amp;summary=yes#jcite">103 L.Ed.2d 290</a> (1989)). Whether the text
of a statute is plain or ambiguous "is determined by reference to the
language itself, the specific context in which the language is used, and the
broader context of the statute as a whole." <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBMT?jcsearch=489%20U.S.%20235&amp;summary=yes#jcite">Id. at 341</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBMT?jcsearch=117%20supreme%20court%20843&amp;summary=yes#jcite">117 S.Ct. 843</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman .
Act), Public Law No. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/1?citation=USACTS%2098-417&amp;summary=yes#jcite">98-417</a> (1984) (codified in relevant part at
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)) set up a statutory system to "balance the need to
stimulate innovation against the goal of furthering the public interest."
H.R. Rep. 98-857, pt. 2, at 2714 (Aug. 1, 1984), 1984 U.S.C.C.A.N. 2686,
2714. This balance is embodied, in part, in the "safe harbor" provision of
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1), which provides (with emphasis added) that:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      It shall not be an act of infringement to make, use, offer to
    sell, or sell within the United States or import into the United
    States a patented invention (other than a new animal drug or
    veterinary biological product (as those terms are used in the
    Federal Food, Drug, and Cosmetic Act and the Act of March 4, 1913)
    which is primarily manufactured using recombinant DNA, recombinant
    <span CLASS="page_no" data-cite="103 uspq 2d 1806" data-cite-type="ReporterOfDecisions" data-cite-pageno="1806" data-primary-citation="103 U.S.P.Q.2d 1800">[**1806]</span> RNA, hybri &mdash; doma technology, or other processes involving site
    specific genetic manipulation techniques) <i>solely for uses reasonably</i>
    <i>related to the development and submission of information under a</i>
    <i>Federal law</i> which regulates the manufacture, use, or sale of drugs
    or veterinary biological products.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Congress could not have been clearer in its choice of words: as long as the
use of the patented invention is solely for uses "reasonably related" to
developing and submitting information pursuant to "a Federal law" regulating
the manufacture, use, or sale of drugs, it is not "an act of infringement."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_925351" href="#headnote_pq2-dec_925351">[1]</a> Although the Hatch-Waxman safe harbor provision was enacted in the context
of the then-novel ANDA approval process, <span CLASS="page_no" data-cite="2012 bl 196196 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1) does not
reference the portion of the Federal Food, Drug, and Cosmetic Act describing
the ANDA requirements, e.g., <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j). Instead, Congress used more
flexible and expansive language to define the scope of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>,
referring generally to "the development and submission of information under
a Federal law which regulates the manufacture, use, or sale of drugs." This
broad language unambiguously applies to submissions under any federal law,
providing that the law "regulates the manufacture, use, or sale of drugs."
Limiting the scope of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1) to just the submission of
information pursuant to the Federal Food, Drug, and Cosmetic Act generally,
or to the ANDA provision of the Federal Food, Drug, and Cosmetic Act in
specific, would read words into the statute in violation of the express
language chosen by Congress.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This interpretation is also consistent with the rest of the statutory
scheme. When Congress wanted to impose a limitation
<span CLASS="page_no" data-cite="686 f 3d 1355" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1355" data-primary-citation="686 F.3d 1348">[*1355]</span> 
based on the Federal Food, Drug, and Cosmetic Act, it expressly referenced
the Act. For example, in the safe harbor provision, Congress excluded "a new
animal drug or veterinary biological product (as those terms are used in the
<i>Federal Food, Drug, and Cosmetic Act</i> and the Act of March 4, 1913)" made
using certain genetic techniques. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1) (emphasis added).
Likewise, when Congress wanted to limit the statute to just a certain kind
of submission, for example the submission of an ANDA application under
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j), it specifically referenced the statutory section
governing those submissions. For example, in the subsection immediately
following the safe harbor, Congress defined as an act of infringement the
submission of "an application under <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)&amp;summary=yes#jcite">section 505(j)</a> of the Federal Food,
Drug, and Cosmetic Act [codified at <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)] or described in
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(2)&amp;summary=yes#jcite">section 505(b)(2)</a> of such Act for a drug claimed in a patent or the use of
which is claimed in a patent." <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20usc%20271&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Unlike the closely related infringement provision, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20usc%20271&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2),
Congress did not link the safe harbor to the submission of an application
for approval under the Federal Food, Drug, and Cosmetic Act.
<i>Compare</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20usc%20271&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1) .(not an act of infringement when used for "the
development and submission of information under a Federal law")
<i>with</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20usc%20271&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A) (it is an act of infringement to submit "an
application under section 505(j) of the Federal Food, Drug, and Cosmetic Act
or described in section <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(2)&amp;summary=yes#jcite">505(b)(2)</a> of such Act"). We cannot change the
statutory language. We will not import the limitation of &sect; 271(e)(2) into &sect;
271(e)(1). "[O]ur obligation is to take statutes as we find them." <i>Diamond</i>
<i>v. Chakrabarty</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. 303</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">315</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CA06?jcsearch=65%20l%20ed%202d%20144&amp;summary=yes#jcite">65 L.Ed.2d 144</a> (1980);
<i>see also, e.g., Reiter v. Sonotone Corp.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5C9PM?jcsearch=442%20us%20330&amp;summary=yes#jcite">442 U.S. 330</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5C9PM?jcsearch=442%20us%20330&amp;summary=yes#jcite">344</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5C9PM?jcsearch=99%20supreme%20court%202326&amp;summary=yes#jcite">99 S.Ct. 2326</a>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5C9PM?jcsearch=60%20l%20ed%202d%20931&amp;summary=yes#jcite">60 L.Ed.2d 931</a> (1979) ("We must take the statute as we find it."). The
statute here applies to <i>any</i> use of a patented invention as long as the use
is "reasonably related to the development and submission of information
under a Federal law which regulates the manufacture, use, or sale of drugs.
. . ." <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In light of these provisions, the only coherent and consistent
interpretation of "a Federal law which regulates the manufacture, use, or
sale of drugs" is that it must be broad enough to encompass submissions made
pursuant to the Federal Food, Drug, and Cosmetic Act. Since <span CLASS="page_no" data-cite="2012 bl 196196 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> there is no
ambiguity in the language used by Congress in <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1), our
inquiry into the scope of the safe harbor is complete. <i>Robinson</i>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CCSA?jcsearch=519%20us%20337&amp;summary=yes#jcite">519 U.S. at 340</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CCSA?jcsearch=117%20supreme%20court%20843&amp;summary=yes#jcite">117 S.Ct. 843</a>. When the intent of Congress is expressed so
clearly and consistently throughout the statute, there is neither the need
nor the occasion to refer to the legislative history. <i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CCSA?jcsearch=519%20U.S.%20337&amp;summary=yes#jcite">Id</a>.</i> The scope of the
Hatch-Waxman safe harbor does not stop at activities reasonably related to
development of information submitted in an ANDA. Instead, the safe harbor
applies "to the development and submission of information under a Federal
law which regulates the manufacture, <span CLASS="page_no" data-cite="103 uspq 2d 1807" data-cite-type="ReporterOfDecisions" data-cite-pageno="1807" data-primary-citation="103 U.S.P.Q.2d 1800">[**1807]</span> use, or sale of drugs or veterinary
biological products." As long as the allegedly infringing use is "for uses
reasonably related" to the development and submission of that information it
is not an act of infringement, regardless of where that requirement resides
in the law.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This analysis is not groundbreaking: the Supreme Court came to essentially
the same conclusion in 1990. In <i>Eli Lilly &amp; Co. v. Medtronic, Inc.</i>, the
Court explained that "the phrase `a Federal law which regulates the
manufacture, use, or sale of
<span CLASS="page_no" data-cite="686 f 3d 1356" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1356" data-primary-citation="686 F.3d 1348">[*1356]</span> 
drugs' more naturally summons up the image of <i>an entire statutory scheme of</i>
<i>regulation</i>," and not just a particular provision of the law. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. 661</a>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">666</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20l%20ed%202d%20605&amp;summary=yes#jcite">110 L.Ed.2d 605</a> (1990) (emphasis added). Although the
legislative history of the safe harbor only mentioned drugs, <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20U.S.%20661&amp;summary=yes#jcite">id., at 669</a> n.
2, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>, the Court nevertheless concluded that the safe harbor
also extended to medical devices, which were also part of "a Federal law
which regulates the manufacture, use or sale of drugs," namely the Federal
Food, Drug, and Cosmetic Act, <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20U.S.%20661&amp;summary=yes#jcite">id. at 674</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Court later reaffirmed this expansive view, explaining: "we think it
apparent from the statutory text that &sect; 271(e)(1)'s exemption from
infringement extends to all uses of patented inventions that are reasonably
related to the development and submission of <i>any</i> information under the FDCA
[(Food, Drug, and Cosmetic Act)]." <i>Merck KGaA v. Integra Lifesciences I,</i>
<i>Ltd.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. 193</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">202</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=162%20l%20ed%202d%20160&amp;summary=yes#jcite">162 L.Ed.2d 160</a> (2005) (citing <i>Eli</i>
<i>Lilly</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. at 665-69</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>). <i>Merck KGaA</i> expressly rejected
the notion that the safe harbor only applies to information developed during
a clinical trial. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. at 202</a> n. 6, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>. Instead, "the
statutory text makes clear that it provides a wide berth for the use of
patented drugs in <i>activities related to the federal regulatory process." </i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">Id.
at 202</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a> (emphasis added). In light of the unqualified
exemption for uses reasonably related to the development and submission of
information, "[t]here is simply no room in the statute for excluding certain
information from the exemption on the basis of the phase of research in
which it is developed or <i>the particular submission in which it could be</i>
<i>included." <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">Id</a>.</i> (emphasis added). The use of the word "under" in the statute
is expansive. <i>Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1HF9EA003?jcsearch=132%20S.%20Ct.%201670&amp;summary=yes#jcite">566 U.S. ___</a>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1HF9EA003?jcsearch=132%20supreme%20court%201670&amp;summary=yes#jcite">132 S.Ct. 1670</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1HF9EA003?jcsearch=132%20supreme%20court%201670&amp;summary=yes#jcite">1683-84</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1HF9EA003?jcsearch=182%20l%20ed%202d%20678&amp;summary=yes#jcite">182 L.Ed.2d 678</a> (2012). "Under a federal law"
extends beyond just the "most barebones information" required by the FDA,
and instead encompasses all "materials the FDA demands in the regulatory
process." <i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While it is clear that the safe harbor applies to a broad set of
"activities related to the federal regulatory process," <i>Merck KGaA</i>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. at 202</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>, there is an important limitation: <span CLASS="page_no" data-cite="2012 bl 196196 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> the use
must be "for uses reasonably related to the development and submission of
information," <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1). "Reasonably related," however, does not
mean that the use of the patented invention must necessarily result in
submission of information to the FDA: "Congress did not limit <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>'s
safe harbor to the development of information for inclusion in a submission
to the FDA; nor did it create an exemption applicable only to the research
relevant to filing an ANDA for approval of a generic drug." <i>Merck KGaA</i>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. at 206</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>. Instead, the Court explained that the safe
harbor "exempted from infringement <i>all</i> uses of patented compounds
`reasonably related' to the process of developing information for submission
under <i>any</i> federal law regulating the manufacture, use, or distribution of
drugs." <i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">Id</a>.</i> (emphasis in original). Thus, the Court explicitly rejected the
notion that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> was limited "to the activities necessary to seek
approval of a generic drug." <i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">Id.</a></i> As long as the accused infringer "has a
reasonable basis for believing" that use of the patented invention might
yield information that "would be appropriate to include in a submission to
the FDA, that use is `reasonably related' to the `development and submission
<span CLASS="page_no" data-cite="686 f 3d 1357" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1357" data-primary-citation="686 F.3d 1348">[*1357]</span> 
of information under . . . Federal law.'" <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">Id. at 207</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_925352" href="#headnote_pq2-dec_925352">[2]</a> At the outset we are met with the contention that the information in
question was not "submitted" to the FDA, <i>see</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20usc%20271&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1) (". . .
solely for uses reasonably related to the development and <i>submission</i> of
information . . ."), but rather was retained by the ANDA holder. We do not
agree. Amphastar, as a generic drug manufacturer under an ANDA, cannot sell
a batch of enoxaparin unless it has established that its strength and
quality is consistent with the standards set forth in the relevant official
compendium. <i>See</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5MC003?jcsearch=21%20usc%20331&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a), <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OG003?jcsearch=21%20Usc%20351(b)&amp;summary=yes#jcite">351</a>(b). FDA regulations require that all
records associated with a produced batch of drugs, including these batch
records, "be retained for at least 1 year after the expiration date of the
batch." <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4KK003?jcsearch=21%20C.F.R.%20%20211.180(a)&amp;summary=yes#jcite">21 C.F.R. &sect; 211.180</a>(a). <span CLASS="page_no" data-cite="103 uspq 2d 1808" data-cite-type="ReporterOfDecisions" data-cite-pageno="1808" data-primary-citation="103 U.S.P.Q.2d 1800">[**1808]</span> These records "shall be readily available
for authorized inspection" by the FDA at any time. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4KK003?jcsearch=21%20C.F.R.%20%20211.180(c)&amp;summary=yes#jcite">21 C.F.R. &sect; 211.180</a>(c).
We think that the requirement to maintain records for FDA inspection
satisfies the requirement that the uses be reasonably related to the
development and submission of information to the FDA. It is not disputed by
the parties that these records are produced in order to develop and submit
to the FDA proof that the Amphastar products comply with a Federal law. The
fact that the FDA does not in most cases actually inspect the records does
not change the fact that they are for the "development and submission of
information under a Federal law." <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1); <i>cf. Merck KGaA</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">545
U.S. at .207</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a> (holding that uses which are not ultimately
included in a submission to the FDA are nonetheless exempted by the safe
harbor). Thus, we consider this information "submitted" for purposes of the
statute. We turn then to the question of whether these submissions are
within the safe harbor.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Merck KGaA v. Integra Lifesciences I, Ltd.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. 193</a>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=162%20l%20ed%202d%20160&amp;summary=yes#jcite">162 L.Ed.2d 160</a> (2005), the Supreme Court held that uses of
patented inventions in preclinical research, the results of which are not
ultimately included in a submission <span CLASS="page_no" data-cite="2012 bl 196196 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> to the FDA, are nevertheless exempted
from infringement by the safe harbor provision. <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">Id. at 208</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>.
The Court explained that
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Congress did not limit <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>'s safe harbor to the
    development of information for inclusion in a submission to the FDA;
    nor did it create an exemption applicable only to the research
    relevant to filing an ANDA for approval of a generic drug. Rather,
    it exempted from infringement <i>all</i> uses of patented compounds
    "reasonably related" to the process of developing information for
    submission under <i>any</i> federal law regulating the manufacture, use, or
    distribution of drugs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">Id. at 206</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>. Thus, it was not an act of infringement to use
patented compounds in preclinical studies which were not ultimately
submitted to the FDA where "there [was] a reasonable basis for believing
that the experiments [would] produce the types of information that are
relevant to an IND or NDA." <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">Id. at 208</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  However, in <i>Classen Immunotherapies, Inc. v. Biogen IDEC</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20f%203d%201057&amp;summary=yes#jcite">659 F.3d 1057</a>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20f%203d%201057&amp;summary=yes#jcite">1070</a> (Fed.Cir.2011), we held that &sect; 271(e)(1) "does not apply to information
that may be routinely reported to the FDA, long after marketing approval has
been obtained."
<span CLASS="page_no" data-cite="686 f 3d 1358" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1358" data-primary-citation="686 F.3d 1348">[*1358]</span> 
At issue in <i>Classen</i> were studies to evaluate the association between the
timing of childhood vaccinations and the risk of developing certain
immune-mediated disorders. The studies themselves were not mandated by the
FDA, but any vaccine license holder was required to report to the FDA
"adverse experience information," such as adverse side effects, it acquired
as a result of vaccine studies. <i>See</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ8FE003?jcsearch=21%20cfr%20600%2080&amp;summary=yes#jcite">21 C.F.R. &sect; 600.80</a>. We found that the
studies conducted by the vaccine license holder according to patented
methods were not insulated by the safe harbor because the studies did not
facilitate marketing a generic drug by "expedit[ing] development of
information for regulatory approval." <i>Classen</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20f%203d%201057&amp;summary=yes#jcite">659 F.3d at 1070</a>. We, of
course, are bound by the <i>Classen</i> decision unless it is overruled en banc or
by the Supreme Court. Accordingly, the scope of the safe harbor provision
does not extend to "information that may be routinely reported to the FDA,
long after marketing approval has been obtained."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_925353" href="#headnote_pq2-dec_925353">[3]</a> This case, however, fits well within <i>Classen</i> because the information
submitted is necessary both to the continued approval of the ANDA and to the
ability to market the generic drug. Here, the submissions are not "routine
submissions" to the FDA, but instead are submissions that are required to
maintain FDA approval. Amphastar is required to conduct a laboratory
determination of identity and strength of the active ingredient for each
batch of enoxaparin. <i>See</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4K6003?jcsearch=21%20cfr%20211%20165&amp;summary=yes#jcite">21 C.F.R. &sect; 211.165</a>(a). This test must be done
according to the patented methods described in an official compendium, in
this case the United States Pharmacopeia (USP). <i>See</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OG003?jcsearch=21%20usc%20351&amp;summary=yes#jcite">21 U.S.C. &sect; 351</a>(b) (Any
"determination as to strength, quality, or purity shall be made in
accordance with the tests or methods of assay set forth in such
compendium."). Moreover, as described above, FDA regulations require that
all such batch records "be retained for at least 1 year after the expiration
date of the batch," <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4KK003?jcsearch=21%20C.F.R.%20%20211.180(a)&amp;summary=yes#jcite">21 C.F.R. &sect; 211.180</a>(a), and that such records "shall be
readily available for authorized inspection" by the FDA <span CLASS="page_no" data-cite="2012 bl 196196 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> at any time,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4KK003?jcsearch=21%20C.F.R.%20%20211.180(C)&amp;summary=yes#jcite">21 C.F.R. &sect; 211.180</a>(c); <i>see also</i> 21 C.F.R. Sec; 211.186, 211.188, 211.194
(requiring "master production and control records," "batch production and
control records," and "laboratory records"). Failure to comply with these
requirements could result in suspension <span CLASS="page_no" data-cite="103 uspq 2d 1809" data-cite-type="ReporterOfDecisions" data-cite-pageno="1809" data-primary-citation="103 U.S.P.Q.2d 1800">[**1809]</span> or revocation of Amphastar's ANDA
approval to market the drug. <i>See</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5MO003?jcsearch=21%20usc%20335a&amp;summary=yes#jcite">21 U.S.C. &sect; 335a</a>(g), <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(e)&amp;summary=yes#jcite">355</a>(e). Furthermore,
such testing is "a condition for [the drug's] approval and release" into
commerce, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4K6003?jcsearch=21%20C.F.R.%20%20211.165(d)&amp;summary=yes#jcite">21 C.F.R. &sect; 211.165</a>(d), thus acting as a predicate to the ability
to market the ANDA-approved drug to the public.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_925354" href="#headnote_pq2-dec_925354">[4]</a> The submissions to the FDA in this case are anything but "routine" &mdash; they
implicate Amphastar's very ability to continue its FDA approval for its ANDA
and to continue manufacturing and marketing enoxaparin under its ANDA. We
also note that, unlike in <i>Classen</i> where the patented studies performed were
not mandated by the FDA, the information here is not generated voluntarily
by the manufacturer but is generated by FDA requirements the manufacturer is
obligated under penalty of law to follow. Under such circumstances, the
information can be said to have been gathered solely for submission to the
FDA and not, as in <i>Classen</i>, primarily for non-FDA purposes. While Momenta
urges us to adopt the pre-post-approval distinction used by the district
court, we cannot: <i>Classen</i> did riot turn on this artificial distinction, and
the plain language of the statute is not restricted to pre-approval
<span CLASS="page_no" data-cite="686 f 3d 1359" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1359" data-primary-citation="686 F.3d 1348">[*1359]</span> 
activities.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> We therefore hold that post-approval studies that are
"reasonably related to the development and submission of information under a
Federal law which regulates the manufacture, use, or sale of drugs" fall
within the scope of the <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/1?citation=35%20U.S.C.%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> safe harbor.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In this case, Momenta concedes that Amphastar's tests "are conducted <i>in</i>
<i>order to satisfy the FDA's requirements</i> that each batch of enoxaparin that
is sold commercially after FDA approval is actually the same as the brand
name drug." Appellee's Br. at 40-41 (emphasis added); <i>see also</i> J.A. 56
(allegation that the "FDA requires" the accused testing). Under a proper
construction of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1), the fact that Amphastar's testing is
carried out to "satisfy the FDA's requirements" means it falls within the
scope of the safe harbor, even though the activity is carried out after
approval. Unlike <i>Classen</i>, where the allegedly infringing activity "may" have
eventually led to an FDA submission, there is no dispute in this case that
Amphastar's allegedly infringing activities are carried out to "satisfy the
FDA's requirements." The district court's interpretation of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> was
erroneous. Under the correct construction, Momenta cannot establish a
likelihood of success on infringement and the preliminary injunction must be
vacated. <i>Genentech, Inc.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X4K9GE?jcsearch=108%20f%203d%201361&amp;summary=yes#jcite">108 F.3d at 1364</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Momenta also argues that even if <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1) extends to
post-approval activities, Amphastar's testing is not protected because there
are FDA endorsed non-infringing alternatives available. The safe harbor,
however, does not mandate the use of a noninfringing alternative when one
exists. The only limitation in the safe harbor is that the use must be
"reasonably related to the development and submission of information"
pursuant <span CLASS="page_no" data-cite="2012 bl 196196 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> to a federal law regulating the "manufacture, use, or sale of drugs
or veterinary biological products." <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1). The safe harbor's
protection is not limited to the dire situation where the patented invention
is the only way to develop and submit the information. Instead, the safe
harbor expressly allows the submitter the freedom to use an otherwise
patented means to develop the necessary information demanded by the "Federal
law." This makes good sense because it eliminates liability for infringement
when that act of infringement is, in effect, required by the federal
government as part of the continuing safety and efficacy monitoring of an
approved drug. It also avoids the situation here, where a drug has received
approval, but is nevertheless kept from the market based on an FDA mandated
testing requirement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Momenta's interpretation is predicated upon the incorrect assumption that
"solely" in the context of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1) means that the patented
invention must be the "sole" means of providing the information for the safe
harbor to apply. This is not the language of the statute: under
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1), as long as the use is "reasonably related to the
development and submission of information" under a relevant statute, it is
not an act of infringement. "Solely" modifies "uses reasonably
<span CLASS="page_no" data-cite="686 f 3d 1360" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1360" data-primary-citation="686 F.3d 1348">[*1360]</span> 
related to the development and submission of information," but does not
place any other restriction on when the patented invention <span CLASS="page_no" data-cite="103 uspq 2d 1810" data-cite-type="ReporterOfDecisions" data-cite-pageno="1810" data-primary-citation="103 U.S.P.Q.2d 1800">[**1810]</span> may be used
without infringing. As long as the use of the patented invention is done to
generate information that will be submitted pursuant to a relevant federal
law, that use falls within the safe harbor. <i>Merck KGaA</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. at 205-206</a>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>. Momenta is therefore incorrect that the possibility that the
FDA would accept the use of other, non-patented, testing methods for the
development and submission of information precludes Amphastar from relying
on the safe harbor in this case.<a HREF="#fn200" name="fnref_fn200">[fn2]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Even if Momenta's strained reading of the statute was supportable,
Amphastar's allegedly infringing activities are clearly carried out
according to the dictates of the Federal Food, Drug, and Cosmetic Act. Under
the Act, Amphastar is prohibited from selling a drug if it is adulterated.
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a). A drug is adulterated if it purports to be a drug listed
in an official compendium, for example the USP, but in actuality differs in
composition. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OG003?jcsearch=21%20U.S.C.%20%20351(b)&amp;summary=yes#jcite">21 U.S.C. &sect; 351</a>(b); <i>see also</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5M2003?jcsearch=21%20usc%20321&amp;summary=yes#jcite">21 U.S.C. &sect; 321</a>(j) (defining
"official compendium"). In order to demonstrate that a drug is not
adulterated, testing must be carried out pursuant to the methods articulated
in the compendium, in this case the USP. <i>See</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OG003?jcsearch=21%20usc%20351&amp;summary=yes#jcite">21 U.S.C. &sect; 351</a>(b) (Any
"determination as to strength, quality, or purity shall be made in
accordance with the tests or methods of `assay set forth in such
compendium."). "For each batch of drug product, there shall be appropriate
laboratory determination of . . . the identity and strength of each active
ingredient. . . ." <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4K6003?jcsearch=21%20C.F.R.%20%20211.165(d)&amp;summary=yes#jcite">21 C.F.R. &sect; 211.165</a>(a). FDA regulations characterize this
testing as "a condition for [the drug's] approval and release" into
commerce. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4K6003?jcsearch=21%20C.F.R.%20%20211.165(d)&amp;summary=yes#jcite">21 C.F.R. &sect; 211.165</a>(d). The FDA also mandates maintenance of
appropriate records related to this type of testing.
<i>See</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4KK003?jcsearch=21%20cfr%20211%20180&amp;summary=yes#jcite">21 C.F.R. &sect; 211.180</a>(a) (production, control, and distribution records
<span CLASS="page_no" data-cite="2012 bl 196196 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> associated with a batch of drug must be retained for at least one year after
the expiration date of the batch); <i>see also</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4KQ003?jcsearch=21%20cfr%20211%20186&amp;summary=yes#jcite">21 C.F.R. &sect; 211.186</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4KS003?jcsearch=21%20C.F.R.%20211.188&amp;summary=yes#jcite">211.188</a>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XMJ4KS003?jcsearch=21%20C.F.R.%20211.188&amp;summary=yes#jcite">211.194</a> (requiring "master production and control records," "batch
production and control records," and "laboratory records").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The USP entry for enoxaparin, the drug at issue in this litigation,
states: "About 20 percent of the materials contain a 1, 6-anhydro derivative
on the reducing end of the chain, the range being between 15 and 25
percent." J.A. 365 (USP Revision Bulletin, Official December 1, 2008). Thus,
in order to be "enoxaparin" as defined in the
<span CLASS="page_no" data-cite="686 f 3d 1361" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1361" data-primary-citation="686 F.3d 1348">[*1361]</span> 
USP entry, the marketed drug product must contain between 15 and 25 percent
of the 1, 6-anhydro derivative. <i><cite>Id</cite>.; see also</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OG003?jcsearch=21%20U.S.C.%20%20351(b)&amp;summary=yes#jcite">21 U.S.C. &sect; 351</a>(b) (drug
adulterated if purports to be a drug in an official compendium but its
strength, quality, or purity differs from the standard set forth in the
compendium). The USP also includes a specific test for the 1, 6-anhydro
derivative, which "involves HPLC analysis of a depolymerized enoxaparin
sodium solution by a mixture of heparinases." J.A. 369 (USP Method &lt;207&gt;).
As the district court explained: "Claims 6, 16, and 53 of the '886 patent
describe how to analyze a sample of enoxaparin to ensure its conformity to
the USP Monograph standard." J.A. 8. Amphastar is required by the FDA to use
this test in order to ensure its enoxaparin is not adulterated.
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5OG003?jcsearch=21%20usc%20351&amp;summary=yes#jcite">21 U.S.C. &sect; 351</a>(b). This testing, which generates information for submission
pursuant to the Food, Drug, and Cosmetic Act, therefore falls squarely
within the scope of the safe harbor.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, the dissent suggests that we must reject any disequilibrium
between <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ032003?jcsearch=35%20U.S.C.%20%20201&amp;summary=yes#jcite">sections 201</a> and <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">202</a> of the Hatch-Waxman Act, that is, the safe
harbor should not be available unless a patent term extension is also
available. Dissenting Op. at 1370-71. This is not correct. The Supreme Court
in <i>Eli Lilly</i> noted that equilibrium was not always achieved. <i>See Eli' Lilly</i>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. at 671-72</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>. We too have rejected this strict
interpretation of the safe harbor, <span CLASS="page_no" data-cite="103 uspq 2d 1811" data-cite-type="ReporterOfDecisions" data-cite-pageno="1811" data-primary-citation="103 U.S.P.Q.2d 1800">[**1811]</span> explaining that "statutory symmetry is
preferable but not required." <i>Abtox</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X36F2O?jcsearch=122%20f%203d%201019&amp;summary=yes#jcite">122 F.3d at 1029</a> (holding that Class II
medical devices, which are not subject to a "rigorous premarket approval
process" and thus cannot receive patent term extensions, are nonetheless
covered by the safe harbor).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_925355" href="#headnote_pq2-dec_925355">[5]</a> Under the correct interpretation of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1), Momenta's
admission that Amphastar's testing is carried out to "satisfy the FDA's
requirements," Appellee's Brief at 40-41, makes it unlikely that Momenta
will succeed on the merits of its infringement claim. The district court's
findings with respect to the irreparable harm, balance of the hardships, and
public interest factors were all, to some extent, predicated on its
erroneous conclusion that Momenta's patent was likely infringed by
Amphastar's product. <i>See</i> J.A. 24 (applying a presumption of irreparable harm
in view of Momenta's "showing of infringement and validity"); J.A. 29
(explaining that in light of the "showing of likelihood of success on the
merits, the balance of hardship tips in [Momenta's] favor"); J.A. 30 (public
interest favors protection of patent rights secured by valid patents).
Because Momenta has not established a likelihood of success <span CLASS="page_no" data-cite="2012 bl 196196 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> on its claim of
infringement, the preliminary injunction must be vacated.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On remand, the district court may want to consider whether Momenta's
admission that Amphastar's use of the patented invention is to "satisfy the
FDA's requirements" makes this case amenable to summary judgment of
non-infringement in favor of Amphastar. Because the safe harbor issue is
dispositive, we need not reach the other arguments on appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>VACATED AND REMANDED.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  COSTS
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Costs to Appellants.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> We are puzzled by the dissent's claim that the use of the words
"solely" and "submitted" require us to limit the statute to pre-approval
activities. This is not the plain meaning of those words. For example, if
the FDA required post-approval testing with subsequent submission of those
test results, those test results were clearly generated "solely" for an FDA
submission and equally clearly were "submitted" to the agency. "Solely" and
"submitted" in no manner limit <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> to "pre-approval testing."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> Although the parties do not argue that FDA-mandated quality control
testing during manufacturing is not done "solely" for purposes of developing
and submitting information to the FDA, the dissent suggests that because
Amphastar uses the patented method while manufacturing a product to sell in
commerce its infringing activity does not meet the "solely" limitation in
the statute. This is not a tenable reading of the statute, and is indeed
contrary to precedent. The Supreme Court cases interpreting the safe harbor
make clear that the safe harbor is not limited to acts which only produce
information for the FDA but protects <i>all</i> acts, even interim research steps
and acts that might produce other useful data, "as long as there is a
reasonable basis for believing that the [act] will produce the types of
information that are relevant to [a submission to the FDA]." <i>Merck</i>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. at 208</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>. We have interpreted this language of the
safe harbor to allow alleged infringers to use "data from tests for more
than FDA approval," such as for fund raising and other business purposes.
<i>Abtox, Inc. v. Exitron Corp.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X36F2O?jcsearch=122%20f%203d%201019&amp;summary=yes#jcite">122 F.3d 1019</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X36F2O?jcsearch=122%20f%203d%201019&amp;summary=yes#jcite">1030</a> (Fed.Cir.1997) (holding
that the alleged infringer's "intent or alternate uses [of test data] are
irrelevant to its qualification to invoke the <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/1?citation=35%20U.S.C.%20271(e)(1)&amp;summary=yes#jcite">section 271(e)(1)</a> shield").
</p></div>
</div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  RADER, Chief Judge, dissenting.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  By definition, a patent defines a right to exclude. Consistent with
property principles, an infringer of a valid patent is an unlawful
trespasser. The remedy for trespassing,
<span CLASS="page_no" data-cite="686 f 3d 1362" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1362" data-primary-citation="686 F.3d 1348">[*1362]</span> 
in this area of property law as well as others, is removal of the
trespasser. Indeed even the Constitution acknowledges the patent owner's
right to exclude trespassers. U.S. Const. art. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/1?citation=USCONST%20Art.%20I&amp;summary=yes#jcite">I</a>, &sect; <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X10V1NQ003?jcsearch=U.S.%20Const.%20art.%20I,%20%208&amp;summary=yes#jcite">8</a>, cl. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X10V1NQ003?jcsearch=U.S.%20Const.%20art.%20I,%20%208&amp;summary=yes#jcite">8</a>. Thus,
exceptions to the traditional property remedy amount to a
get-out-of-jail-free card for the trespasser. Accordingly, such exceptions
must occur only sparingly with awareness that this license allows the
wrongdoer free reign to continue trespassing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The public readily applauds the role of patents in the development and
delivery to the marketplace of life-saving drugs or modern technology
products like smart-phones. At the same time, many incremental advances
contribute to these monumental advances or, as in this case, enhance their
delivery to the public. These incremental inventions also represent
difficult and expensive advances in technology. For example, in this case,
Amphastar had a strong incentive to invent this patented manufacturing
method. As the first-filer, it would have obtained 180 days of market
exclusivity as the only seller of the generic drug &mdash; a right worth $260
million per quarter. Nevertheless, Amphastar could not make that invention.
Instead, the patentee Momenta made the investment, did the research, and
engineered the new method disclosed in the '<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X3H8SA841GJ?jcsearch=usp%207575886&amp;summary=yes#jcite">886 patent</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At that point, Amphastar stepped in and took Momenta's patented invention
without permission and used it to manufacture each commercial batch it sells
on the market. Indeed Amphastar continues to tres-pass and promises to
trespass for years to come. In fact, as the court repeatedly acknowledges,
Amphastar is only able to compete with Momenta by taking its patented
invention. Amphastar has not developed its own method, but instead delights
in trespassing and refuses to pay a reasonable royalty to make the trespass
lawful.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court would allow this arrogance to continue by expanding the limited
reach of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1). This expansion of the law circumvents the
purpose of the law and ignores the binding precedent of <i>Classen</i>
<i>Immunotherapies, Inc. v. Biogen IDEC</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20f%203d%201057&amp;summary=yes#jcite">659 F.3d 1057</a> (Fed.Cir.2011). Sadly
this result will render worthless manufacturing test method patents.
Accordingly, I must respectfully dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court has observed that the text alone of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> can be
"not plainly comprehensible." <i>Eli Lilly &amp; Co. v. Medtronic, Inc.</i>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. 661</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">669</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20l%20ed%202d%20605&amp;summary=yes#jcite">110 L.Ed.2d 605</a> (1990). The purpose of
this <span CLASS="page_no" data-cite="103 uspq 2d 1812" data-cite-type="ReporterOfDecisions" data-cite-pageno="1812" data-primary-citation="103 U.S.P.Q.2d 1800">[**1812]</span> text, which ought to inform its application, however, is evident from
the legislative <span CLASS="page_no" data-cite="2012 bl 196196 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> history. The legislative history of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> includes
more than 2 House reports, 25 statements and letters, and many pages of
Congressional testimony. A review of this extensive material shows that
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">section 202</a> of the Hatch-Waxman Act, enacted as <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>, had the sole
purpose of overruling this court's holding in <i>Roche Products, Inc. v. Bolar</i>
<i>Pharmaceutical Co.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X3J5E7?jcsearch=733%20f%202d%20858&amp;summary=yes#jcite">733 F.2d 858</a> (Fed. Cir.1984). In particular, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>
applied only in limited situations, namely pre-approval experiments to
obtain FDA approval:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The purpose of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">271(e)(1)</a> and <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">(2)</a> is to establish that
    <b>experimentation</b> with a patented drug product, when the purpose is to
    prepare for commercial activity which will begin after a valid
    patent expires, is not a patent infringement. Since the Committee's
    Subcommittee on
<span CLASS="page_no" data-cite="686 f 3d 1363" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1363" data-primary-citation="686 F.3d 1348">[*1363]</span> 
    Health and the Environment began consideration of this bill, the
    Court of Appeals for the Federal Circuit held that this type of
    <b>experimentation</b> is infringement. In <i>Roche Products, Inc. v. Bolar</i>
    <i>Pharmaceutical Co.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X3J5E7?jcsearch=733%20f%202d%20858&amp;summary=yes#jcite">733 F.2d 858</a> (Fed. Cir.1984), the Court of
    Appeals for the Federal Circuit held that the <b>experimental use</b> of a
    drug product prior to the expiration date of a patent claiming that
    drug product constitutes patent infringement, even though <b>the only</b>
    <b>purpose of the experiments is to seek FDA approval</b> for the
    commercial sale of the drug after the patent expires. It is the
    Committee's view that <b>experimental activity</b> does not have any
    adverse economic impact on the patent owner's exclusivity during the
    life of a patent, but prevention of such activity would extend the
    patent owner's commercial exclusivity beyond the patent expiration
    date.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
H.R.Rep. No. 98-857, pt. 1, at 45-46 (1984), 1984 U.S.C.C.A.N. 2647,
2678-2679 (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The provisions of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">section 202</a> of the bill have the net effect of
    reversing the holding of the court in <i>Roche Products, Inc. v. Bolar</i>
    <i>Pharmaceutical Co.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X3J5E7?jcsearch=733%20f%202d%20858&amp;summary=yes#jcite">733 F.2d 858</a> (Fed.Cir.1984).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
H.R.Rep. No. 98-857, pt. 2, at 27 (1984), 1984 U.S.C.C.A.N. 2686 at 2711.
<i>See also Innovation and Patent Law Reform: Hearing on H.R. 3605 Before the</i>
<i>Subcomm. on Courts, Civil Liberties and the Admin, of Justice of the H.</i>
<i>Comm. on the Judiciary</i>, 98th Cong. 742 (1984) (statement of Laurence H.
Tribe, Professor of Law, Harvard Law School) ("<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">Section 202</a>, the thrust of
which is to overturn <i>Roche v. Bolar</i> legislatively"); <i>Innovation and Patent</i>
<i>Law Reform: Hearing on H.R. 3605 Before the Subcomm. on Courts, Civil</i>
<i>Liberties and the Admin, of Justice of the H. Comm. on the Judiciary</i>, 98th
Cong. 826 (1984) (letter from Bernarr R. Pravel, President, American
Intellectual Property Law Association) ("<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">Section 202</a> is intended to reverse
the April 23, 1984, decision of the Court of Appeals for the Federal Circuit
in <i>Roche Products, Inc. v. Bolar Pharmaceutical Co.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X3J5E7?jcsearch=733%20f%202d%20858&amp;summary=yes#jcite">733 F.2d 858</a>
(Fed.Cir.1984)."); Memorandum from Congressional Research Service, The
Library of Congress, American Law Division to House Judiciary Committee,
<i>located at</i> H.R.Rep. No. 98-857, pt. 2, at 27 n.18 (1984),
1984 U.S.C.C.A.N. 2686 at 2711.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Roche v. Bolar</i> held that the limited pre-approval experiments to obtain
FDA approval still infringed a valid patent. <i>See</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X3J5E7?jcsearch=733%20f%202d%20858&amp;summary=yes#jcite">733 F.2d at 861</a> ("The
district court correctly recognized that the issue in this case is narrow:
does the <b>limited</b> use of a patented drug <b>for testing and investigation</b>
<b>strictly related to FDA drug approval <span CLASS="page_no" data-cite="2012 bl 196196 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> requirements during the last 6 months</b>
<b>of the term of the patent</b> constitute a use which, unless licensed, the
patent statute makes actionable?" (emphasis added)). In overturning <i>Roche v.</i>
<i>Bolar</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> allowed pharmaceutical companies to conduct such
experiments to obtain FDA approval. The new section enabled those companies
to begin the approval process while the patent is still in force, so that
they can obtain FDA approval and begin selling immediately <i>after</i> the
patent's life. Otherwise, the safety testing processes would have to wait
until after the patent's life ends thus creating a lag in time when the
patent would not be in force yet the companies could not enter the market
pending FDA approval:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      <b>In order to complete this application</b> the generic manufacturer
    must conduct certain drug tests. In order to
<span CLASS="page_no" data-cite="686 f 3d 1364" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1364" data-primary-citation="686 F.3d 1348">[*1364]</span> 
    facilitate this type of testing, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">section 202</a> of the bill creates
    general exception to the rules of patent infringement. Thus, a
    generic manufacturer may obtain a supply of a patented drug product
    during the life of the patent and conduct tests using that product
    <b>if the purpose of those tests is to submit an application to FDA for</b>
    <b>approval.<span CLASS="page_no" data-cite="103 uspq 2d 1813" data-cite-type="ReporterOfDecisions" data-cite-pageno="1813" data-primary-citation="103 U.S.P.Q.2d 1800">[**1813]</span> </b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/1?citation=130%20Cong.%20Rec.%2023060&amp;summary=yes#jcite">130 CONG. REC. 23060</a> (1984) (statement of Rep. Robert W. Kastenmeier,
Chairman of the Subcommittee on Courts, Civil Liberties and the
Administration of Justice, Committee on the Judiciary) (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Pharmaceutical Manufacturers Association echoed the Chairman's
analysis of the purpose of the bill:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The sponsors and supporters of the legislation have agreed from
    the beginning that generic products should not be approved for
    marketing prior to the expiration of a valid patent as extended
    under the legislation. In return, there has been a compromise
    agreement that pre-<b>approval testing</b> could be conducted prior to the
    expiration of the patent, as extended, so that marketing could begin
    immediately thereafter. Therefore, the bill reverses the <i>Roche v.</i>
    <i>Bolar</i> decision to permit a generic company to "use" a patented
    product <b>for the limited purpose of completing the testing necessary</b>
    <b>for FDA approval.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Innovation and Patent Law Reform: Hearing on H.R. 3605 Before the Subcomm.</i>
<i>on Courts, Civil Liberties and the Admin, of Justice of the H. Comm. on the</i>
<i>Judiciary</i>, 98th Cong. 696 (1984) (letter from Pharmaceutical Manufacturers
Association) (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On the other side of the industry, the Generic Pharmaceutical Industry
Association agreed that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">section 202</a> is only for limited pre-approval
experiments:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The purpose of the foregoing provision is to permit a generic drug
    manufacturer to engage in <b>the limited experimental activities which</b>
    <b>are necessary to obtain FDA pre-marketing approval</b> before a patent
    expires so that actual competition between the generic drug and the
    original drug can begin immediately after the patent covering the
    original drug expires. <b></b><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">Section 202</a> <b>does not authorize any activity</b>
    <b>which would deprive the patent owner of the sale of a single tablet</b>
    <b>during the life of a valid patent. In fact, the limited testing</b>
    <b>activity required to obtain FDA approval <span CLASS="page_no" data-cite="2012 bl 196196 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[***17]</span> of a generic drug would not</b>
    <b>normally result in the use of even a single generic tablet for its</b>
    <b>therapeutic purpose during the life of a valid patent.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Innovation and Patent Law Reform: Hearing on H.R. 3605 Before the Subcomm.</i>
<i>on Courts, Civil Liberties and the Admin, of Justice of the H. Comm. on the</i>
<i>Judiciary</i>, 98th Cong. 926 (1984) (memorandum of Alfred B. Engleberg, Patent
Counsel, Generic Pharmaceutical Industry Association) (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The executive branch favored an even more limited exception than the one
proposed in <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">section 202</a> and enacted as <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>. Nevertheless, it clearly
understood the boundaries of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">section 202</a> to be pre-approval experimental
use.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      This letter sets forth the Administration's views on H.R. 3605 . .
    . First, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">section 202</a> of title II should be amended to permit
    experimental use of a drug by a non-patentee only during the period
    in which the affected patent is in restoration period. Existing
    patentees have relied upon accepted doctrine indicating
<span CLASS="page_no" data-cite="686 f 3d 1365" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1365" data-primary-citation="686 F.3d 1348">[*1365]</span> 
    that use of a patented invention <b>for the purpose of obtaining</b>
    <b>regulatory approval</b> infringes that patent. Upsetting expectations of
    this sort could only inhibit future innovation and investment, which
    depend upon the integrity of the patent laws.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Innovation and Patent Law Reform: Hearing on H.R. 3605 Before the Subcomm.</i>
<i>on Courts, Civil Liberties and the Admin, of Justice of the H. Comm. on the</i>
<i>Judiciary</i>, 98th Cong. 812 (1984) (letter from David A. Stockman, Director,
Office of Management and Budget, to Rep. Edward R. Madigan, Subcomm. on
Health and the Environment, H. Comm. on Energy and Commerce) (emphasis
added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The pharmaceutical industry expressed concern about permitting trespass on
exclusive rights, but this concern dissipated with promises that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>
only allowed "limited testing of drugs." <i>See</i> H.R.Rep. No. 98-857, pt. 2, at
29 (1984), 1984 U.S.C.C.A.N. 2686 at 2714.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      In this case the generic manufacturer is not permitted to market
    the patented drug during the life of the patent; all that the
    generic can do is test the drug <b>for purposes of submitting data to</b>
    <b>the FDA for approval.</b> Thus, the nature of the interference is <b><i>de</i></b>
    <b><i>minimis.</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><cite>Id. at 30</cite> (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Specifically, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> won approval because it was limited in time,
quantity, and type. First, as to time, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> only applies to
pre-marketing approval. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/1?citation=130%20Cong.%20Rec.%2023060&amp;summary=yes#jcite">130 CONG. REC. 23060</a> (1984) (statement of Rep.
Robert W. Kastenmeier, Chairman of the Subcommittee on Courts, Civil
Liberties and the Administration of Justice, Committee on the Judiciary)
(<span CLASS="page_no" data-cite="103 uspq 2d 1814" data-cite-type="ReporterOfDecisions" data-cite-pageno="1814" data-primary-citation="103 U.S.P.Q.2d 1800">[**1814]</span> see block quote above); <i>Innovation and Patent Law Reform: Hearing on H.R.</i>
<i>3605 Before the Subcomm. on Courts, Civil Liberties and the Admin, of</i>
<i>Justice of the H. Comm. on the Judiciary</i>, 98th Cong. 696 (1984) (letter from
Pharmaceutical Manufacturers Association) (see block quote above);
<i>Innovation and Patent Law Reform: Hearing on H.R. 3605 Before the Subcomm.</i>
<i>on Courts, Civil Liberties and the Admin, of Justice of the H. Comm. on the</i>
<i>Judiciary</i>, 98th Cong. 742 (1984) (statement of Laurence H. Tribe, Professor
of Law, Harvard Law School) ("<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">Section 202</a>, the thrust of which is to
overturn <i>Roche v. Bolar</i> legislatively, so as to provide that it is <i>not</i> an
infringement to make, use, <span CLASS="page_no" data-cite="2012 bl 196196 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[***18]</span> or sell a patented invention for purposes
`reasonably related' to the development and submission of information to
obtain FDA's <b>premarketing approval</b> to engage in the commercial manufacture,
use, or sale of the drug after patent expiration") (emphasis added);
<i>Innovation and Patent Law Reform: Hearing on H.R. 3605 Before the Subcomm.</i>
<i>on Courts, Civil Liberties and the Admin, of Justice of the H. Comm. on the</i>
<i>Judiciary</i>, 98th Cong. 926 (1984) (memorandum of Alfred B. Engleberg, Patent
Counsel, Generic Pharmaceutical Industry Association) (see block quote
above); Memorandum from Congressional Research Service, The Library of
Congress, American Law Division to House Judiciary Committee, <i>located at</i>
H.R.Rep. No. 98-857, pt. 2, at 27 n.18 (1984), 1984 U.S.C.C.A.N. 2686, 2711
n. 18 ("In <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">&sect; 202</a>, Congress would provide that it is not an infringement to
make, use, or sell a patented invention solely for uses reasonably related
to the development and submission of information <b>for the purpose of</b>
<b>obtaining FDA premarketing approval of a drug.").</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, as to quantity and type, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> only applies to
experimentation &mdash; and therefore would have limited impact on the patentee's
exclusivity during
<span CLASS="page_no" data-cite="686 f 3d 1366" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1366" data-primary-citation="686 F.3d 1348">[*1366]</span> 
the life of the patent. H.R.Rep. No. 98-857, pt. 1, at 45-46 (1984),
1984 U.S.C.C.A.N. 2647 at 2678-2679 (see block quote above); <i>Innovation and</i>
<i>Patent Law Reform: Hearing on H.R. 3605 Before the Subcomm. on Courts, Civil</i>
<i>Liberties and the Admin, of Justice of the H. Comm. on the Judiciary</i>, 98th
Cong. 696 (1984) (letter from Pharmaceutical Manufacturers Association) (see
block quote above); <i>Innovation and Patent Law Reform: Hearing on H.R. 3605</i>
<i>Before the Subcomm. on Courts, Civil Liberties and the Admin, of Justice of</i>
<i>the H. Comm. on the Judiciary</i>, 98th Cong. 742 (1984) (statement of Laurence
H. Tribe, Professor of Law, Harvard Law School) (quoted above); <i>Innovation</i>
<i>and Patent Law Reform: Hearing on H.R. 3605 Before the Subcomm. on Courts,</i>
<i>Civil Liberties and the Admin, of Justice of the H. Comm. on the Judiciary</i>,
98th Cong. 926 (1984) (memorandum of Alfred B. Engleberg, Patent Counsel,
Generic Pharmaceutical Industry Association) (see block quote above).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In particular, the authors made clear that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">section 271(e)(1)</a> would not
apply to commercial sales, i.e., the "infringing" product would not enter
the market until <i>after</i> the patent's life. H.R.Rep. No. 98-857, pt. 1, at 45
(1984), 1984 U.S.C.C.A.N. 2647 at 2678 ("This section <b>does not permit the</b>
<b>commercial sale</b> of a patented drug by the party using the drug to develop
such information, but it does permit the commercial sale of research
quantities of active ingredients to such party.") (emphasis added);
<i>Innovation and Patent Law Reform: Hearing on H.R. 3605 Before the Subcomm.</i>
<i>on Courts, Civil Liberties and the Admin, of Justice of the H. Comm. on the</i>
<i>Judiciary</i>, 98th Cong. 932 (1984) (memorandum of Alfred B. Engleberg, Patent
Counsel, Generic Pharmaceutical Industry Association) ("The <b>limited</b>
<b>`experimental use'</b> permitted by <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">Section 202</a> does not, in any way, impinge on
the exclusive right of the patent owner to make, use and sell the patented
invention for all commercial purposes during the life of the patent. <b>The</b>
<b>permitted experimental use would not result in competitive commercial</b>
<b>activity until all valid patents <span CLASS="page_no" data-cite="2012 bl 196196 p 19" data-cite-type="Bloomberg" data-cite-pageno="19" data-primary-citation="">[***19]</span> expired.")</b> (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The authors of this section (and I hesitate to add that I was present
through this legislative process) did not imagine that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> would
allow <i>continuous, commercial</i> infringing sales during any portion of the life
of the patent. As discussed below, Amphastar has already obtained FDA
regulatory approval, and today this court rewrites the law to allow
Amphastar to infringe Momenta's patent throughout <i>the entire life of</i>
<i>Momenta's patent</i> and for the purpose of obtaining profits on <i>commercial</i>
<i>sales</i> of a product that <i>competes with the patentee.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nowhere in the legislative history can this court find any suggestion that
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> would apply other than in the limited scenario of conducting <i>de</i>
<i>minimis</i> experiments pre-approval (<i>i.e.</i>, to obtain FDA approval). Nowhere in
the legislative history can this court find a hint that an "infringer" could
continue to use its competitor's patented method in manufacture of each
commercial batch for contemporaneous sale. Nowhere in the legislative
<span CLASS="page_no" data-cite="103 uspq 2d 1815" data-cite-type="ReporterOfDecisions" data-cite-pageno="1815" data-primary-citation="103 U.S.P.Q.2d 1800">[**1815]</span> history can this court find any mention of the post-approval, continuous,
commercial sales allowed by this decision. Nowhere in the legislative
history can this court find any suggestion that the mere maintenance or
retention of information as part of a company's records is considered a
submission that would trigger <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>. In fact, this court makes no
attempt to examine the legislative history of this section at all &mdash; a very
telling silence.
<span CLASS="page_no" data-cite="686 f 3d 1367" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1367" data-primary-citation="686 F.3d 1348">[*1367]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Of course, this court proclaims that it finds no ambiguity requiring it to
find out the purpose of the section it distorts. To the contrary, the
Supreme Court found the statute can be ambiguous and "not plainly
comprehensible." <i>See Eli Lilly</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. at 669</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>. Moreover
the court strains to avoid ambiguity by discounting critical statutory
phrases, namely "solely" and "submission."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To facilitate a post-approval, continuous, commercial use, the court
discounts the word "solely." Indeed, throughout its opinion, the court cites
the language of the statute yet omits the word "solely." <i>See</i> Majority Op.
1355, 1355-56, 1356, 1356-57, 1359, 1359-60. If one properly reads "solely"
as the statute says, the result must be that Amphastar's activity is not
within the statute. Its infringing activity is <b>not solely</b> for developing and
submitting information to the FDA. Instead, Amphastar uses this method for
the purpose of manufacturing a product to sell on the market in commerce.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, the court claims that the mere retention of records can satisfy
the "submission" requirement in <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>. By essentially stating that
"submission" can mean not really submitting, this new interpretation reads
this requirement out of the statute as well.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Specifically, despite the plain meaning of "submission of information" to
mean the company actually submitting information to the FDA, the court
interprets "submission of information" to mean the mere retention of
information as part of a company's records. Majority Op. 1357 ("We think
that the requirement to <b>maintain</b> records for FDA inspection satisfies the
requirement that the uses be reasonably related to the development <span CLASS="page_no" data-cite="2012 bl 196196 p 20" data-cite-type="Bloomberg" data-cite-pageno="20" data-primary-citation="">[***20]</span> and
submission of information to the FDA. Thus, we consider this information
`submitted' for purposes of the statute." (emphasis added)), 1358.
Maintaining or keeping a document has the exact opposite meaning of
submitting a document. In other words, "submission" means not really
submitting anything &mdash; a strange construction of an "unambiguous" term.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This new interpretation would allow almost all activity by pharmaceutical
companies to constitute "submission" and therefore justify a free license to
trespass. The FDA can inspect records of any drug manufacturer and seller.
<i>See</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X19762S003?jcsearch=21%20usc%20374&amp;summary=yes#jcite">21 U.S.C. &sect; 374</a>. Thus, the drug manufacturer need only make a record,
which could potentially be inspected by the FDA, and then any activity could
satisfy this new meaning of "submission."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Therefore, a reading of <i>all</i> the words in the statute and a reading of
those words in light of their legislative history shows that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>
only permits a limited amount of pre-approval experiments to obtain FDA
approval. Thus, the statute limits the exception to "solely for uses
reasonably related to the development and submission of information under a
Federal law which regulates the manufacture, use, or sale of drugs or
veterinary biological products."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court has already decided the meaning of this statute in <i>Classen.</i> The
<i>Classen</i> majority held "<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> provides an exception to the law of
infringement in order <b>to expedite development of information for regulatory</b>
<b>approval</b> of generic counterparts of patented products. The statute does not
apply to information that may be routinely reported to the FDA, long after
marketing approval has been obtained." <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20f%203d%201057&amp;summary=yes#jcite">659 F.3d at 1070</a> (emphasis
<span CLASS="page_no" data-cite="686 f 3d 1368" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1368" data-primary-citation="686 F.3d 1348">[*1368]</span> 
added). As support, <i>Classen</i> looked to the legislative history: "The Report
is replete with statements that the legislation concerns <b>premarketing</b>
<b>approval</b> of generic drugs. The Report emphasizes that `The information which
can be developed under this provision is the type which is required <b>to</b>
<b>obtain approval</b> of the drug.'" <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20F.3d%201057&amp;summary=yes#jcite">Id. at 1071</a> (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Classen</i> also looked to Supreme Court precedent, such as <i>Eli Lilly &amp; Co. v.</i>
<i>Medtronic, Inc.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. 661</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20l%20ed%202d%20605&amp;summary=yes#jcite">110 L.Ed.2d 605</a> (1990) and
<i>Merck KGaA v. Integra Lifesciences I, Ltd.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. 193</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=162%20l%20ed%202d%20160&amp;summary=yes#jcite">162 L.Ed.2d 160</a> (2005): "Every decision examining the statute has
appreciated that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> is directed to <b>premarketing approval</b> of generic
counterparts before patent expiration." <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20F.3d%201057&amp;summary=yes#jcite">Id. at 1071</a> (emphasis added). In
particular, <i>Classen</i> stated:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Our colleague in dissent strays from statute and precedent, in
    arguing that any activity <span CLASS="page_no" data-cite="103 uspq 2d 1816" data-cite-type="ReporterOfDecisions" data-cite-pageno="1816" data-primary-citation="103 U.S.P.Q.2d 1800">[**1816]</span> by any entity concerning any adversely
    patented product or method is exempted from infringement by <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect;
    271(e)(1)</a>, provided only that the information obtained is
    `reasonably related to submitting <i>any</i> information under the FDCA,'
    [<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20F.3d%201057&amp;summary=yes#jcite">659 F.3d at 1083</a> (Moore, J., dissenting)] (emphasis in dissent),
    `including information regarding post-<b>approval</b> uses.' <i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20F.3d%201057&amp;summary=yes#jcite">Id</a>.</i> Such a
    massive enlargement of the statutory exemption is incorrect.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20F.3d%201057&amp;summary=yes#jcite">Id. at 1072</a> n. 4 (bold emphasis added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, Amphastar uses Momenta's patented method in the manufacture of each
commercial batch it sells. By definition, its use is not to obtain FDA
approval. One can only market a drug that the FDA has already approved.
<span CLASS="page_no" data-cite="2012 bl 196196 p 21" data-cite-type="Bloomberg" data-cite-pageno="21" data-primary-citation="">[***21]</span> Amphastar is not using Momenta's patented method for pre-approval, limited
experimental use. It is not pre-<i>approval</i> because Amphastar has already
obtained approval. <i>See</i> Appellant Br. 7 (Amphastar received FDA approval on
September 19, 2011.); Majority Op. 1359 ("It also avoids the situation here,
where a drug has received approval . . .") . Thus, its activity is
post-approval. It is not <i>limited</i> because Amphastar uses Momenta's invention
on a continuous basis in the manufacture of each commercial batch and during
the life of Momenta's patent. It is not <i>experimental</i> because Amphastar uses
Momenta's invention in manufacturing each commercial batch of its product
for contemporaneous sale on the market (in commerce) to obtain profits and
to compete with Momenta. This is a commercial use of an invention by a
competitor to compete and trespass on the inventor's exclusive right.
Amphastar's use is not for premarketing FDA approval and therefore <i>Classen</i>
definitively holds that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> does not apply here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To come out the exact opposite way, the court first claims <i>Classen</i> did not
turn on the pre-/post-approval distinction. Majority Op. 1358. Second, the
court claims <i>Classen</i> merely held that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> does not apply to
"routine" submissions. Therefore, this court opines: "This case, however,
fits well within Classen because the information submitted is necessary both
to the continued approval of the ANDA and to the ability to market the
generic drug. Here, the submissions are not `routine submissions' to the
FDA, but instead are submissions that are required to maintain FDA
approval." Majority Op. 1358.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At the outset, this court must stretch too far to claim <i>Classen</i> did not
turn on a pre/post-approval distinction. The dissent actually helps identify
the holding in <i>Classen.</i>
<span CLASS="page_no" data-cite="686 f 3d 1369" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1369" data-primary-citation="686 F.3d 1348">[*1369]</span> 
The <i>Classen</i> dissent stated: "The majority concludes that the district court
incorrectly interpreted the safe harbor of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> because, according to
the majority, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> is limited to pre-<b>approval activities.</b> . . .
Accordingly, I conclude that the safe harbor extends to all uses that are
reasonably related to submitting any information under the FDCA, including
information regarding post-<b>approval</b> uses. . . ." <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20f%203d%201057&amp;summary=yes#jcite">659 F.3d at 1083</a> (emphases
added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Further, the parties and the amici certainly thought <i>Classen</i> turned on a
pre/post-approval distinction. <i>See, e.g.</i>, Classen's Opposition to Petition
for Rehearing En Banc, at *1 ("Plaintiff-Appellant agrees with Hatch-Waxman,
The United States Supreme Court and the Federal Circuit:
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20USC%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1) applies only to pre-<b>market development activities</b>,
there is no safe harbor after the commencement of commercial sales of a
drug. An extension of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20USC%20%20271(e)(1)&amp;summary=yes#jcite">271(e)(1)</a> into the
post-<b>approval/post-commercialization period</b> is outside the scope of the Drug
Price Competition and Patent Term Restoration Act and would present
unworkable difficulties in its application.") (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Moreover, this court in <i>Classen</i> did not at any point state that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect;
271(e)(1)</a> applies to information "necessary both to the continued approval
of the ANDA and to the ability to market the generic drug." Majority Op.
1358. Indeed, this post-approval, <span CLASS="page_no" data-cite="2012 bl 196196 p 22" data-cite-type="Bloomberg" data-cite-pageno="22" data-primary-citation="">[***22]</span> continuous, commercial use is the exact
opposite of the <i>Classen</i> rule. <i>Classen</i> rested its holding on "premarketing
approval," <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20f%203d%201057&amp;summary=yes#jcite">659 F.3d at 1070</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20f%203d%201057&amp;summary=yes#jcite">1071</a>, "limited amount of testing," <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20F.3d%201057&amp;summary=yes#jcite">id. at 1071</a>,
and "experimentation," <i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20F.3d%201057&amp;summary=yes#jcite">id.</a></i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This decision ("post-approval studies"; "after approval"; "not restricted
to pre-approval activities") cannot be genuinely reconciled with <i>Classen</i>
("pre-marketing approval"). Instead, the court in this decision uses the
same language as the dissent in <i>Classen</i> ("post-approval"; "I conclude that
the safe harbor extends to all uses that are reasonably related to
submitting any information under the FDCA, including information regarding
post-approval uses"). This decision should instead request the entire court
to resolve the issue <i>en banc.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The court distinguishes <i>Classen</i> by characterizing the activities in that
case as not "mandated by the FDA," while the activities here <span CLASS="page_no" data-cite="103 uspq 2d 1817" data-cite-type="ReporterOfDecisions" data-cite-pageno="1817" data-primary-citation="103 U.S.P.Q.2d 1800">[**1817]</span> are. Some
context is in order. The patented method here is "mandated" only in that
Momenta thus far has created and developed the only successful method by
which one can show the FDA's requirement has been met. Amphastar is free to
invent its own method to satisfy these requirements. Instead it chooses to
tres-pass. Because it has not ventured to find another way to perform these
tests, it is unfair to suggest that Amphastar's hands are tied. Indeed, to
the extent the court is creating a new expansion of the statute that covers
anything "mandated" by the FDA, this would unfairly attack inventors of the
newest and most successful method. Such a method would be adopted or
"mandated" by the FDA and then trigger the court's new infringement
exception. Needless to say, that would be the exact opposite from a system
that incentivizes creation and improvement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court's interpretation of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> would essentially render
manufacturing method patents worthless. This court repeatedly states that
the FDA's adoption of Momenta's patented method as a standard means that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect;
271(e)(1)</a> should apply. Majority
<span CLASS="page_no" data-cite="686 f 3d 1370" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1370" data-primary-citation="686 F.3d 1348">[*1370]</span> 
Op. 1358 ("the information here is not generated voluntarily by the
manufacturer but is generated by FDA requirements the manufacturer is
obligated under penalty of law to follow"), 1359 ("that act of infringement
is, in effect, required by the federal government as part of the continuing
safety and efficacy monitoring of an approved drug"), <i><cite>id.</cite></i> ("where a drug has
received approval, but is nevertheless kept from the market based on an FDA
mandated testing requirement"), 1359 ("the fact that Amphastar's testing is
carried out to `satisfy the FDA's requirements' means it falls within the
scope of the safe harbor, even though the activity is carried out after
approval"), 1360 ("Amphastar's allegedly infringing activities are clearly
carried out according to the dictates of the Federal Food, Drug, and
Cosmetic Act").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In essence, this reasoning repeals the incentives and protections of the
patent act in this area. A patentee invents the first and (at the time) best
method. Because of the success and utility of the inventive method, the FDA
adopts that method as a standard. Because that method is "required by the
FDA," this court <span CLASS="page_no" data-cite="2012 bl 196196 p 23" data-cite-type="Bloomberg" data-cite-pageno="23" data-primary-citation="">[***23]</span> would permit copiers to infringe. What incentive remains to
invest in inventing a better test? Imagine a teacher who rewards the top
student by allowing her peers to copy her exam answers. Needless to say,
this approach does violence to patent law and future research incentives in
this field.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  And what happens if a second, less effective (patented) method appears?
Will copiers be allowed to infringe that method, too? Or, instead, because
it is not as good and the FDA does not adopt it as the standard, then the
court's new interpretation of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> does not apply and copiers can
infringe the first, best method but not the second, less effective method?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  IV.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court cases <i>Eli Lilly &amp; Co. v. Medtronic, Inc.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. 661</a>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20l%20ed%202d%20605&amp;summary=yes#jcite">110 L.Ed.2d 605</a> (1990) and <i>Merck KGaA v. Integra</i>
<i>Lifesciences I, Ltd</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. 193</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=162%20l%20ed%202d%20160&amp;summary=yes#jcite">162 L.Ed.2d 160</a> (2005)
support the holding in <i>Classen</i> and do not support this decision. Both
holdings in <i>Eli Lilly</i> and <i>Merck</i> dealt with pre-<i>approval</i> activity and
submissions, meaning <i>before</i> obtaining FDA approval. Further, neither even
suggested that the mere maintenance or retention of information as part of a
company's records could be a "submission" to the FDA. Nevertheless, the
court takes phrases from those opinions out of context to allege that its
new interpretation of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> is consistent with those cases.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Eli Lilly</i>, the Supreme Court addressed whether <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> applies to
medical devices in addition to drugs. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. at 663-64</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>
("This case presents the question whether <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(1) renders
activities that would otherwise constitute patent infringement noninfringing
if they are undertaken for the purpose of developing and submitting to the
Food and Drug Administration (FDA) information necessary to obtain marketing
approval for a medical device under <cite>&sect; 515</cite> of the Federal Food, Drug, and
Cosmetic Act (FDCA), <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/1?citation=90%20stat%20552&amp;summary=yes#jcite">90 Stat. 552</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEI5PM003?jcsearch=21%20usc%20360e&amp;summary=yes#jcite">21 U.S.C. &sect; 360e</a>.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court described how <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ032003?jcsearch=35%20U.S.C.%20%20201&amp;summary=yes#jcite">&sect; 201</a> and <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">202</a> should be read together.
Section 201 concerns activity in the early years of a patent's life. Section
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">202</a> concerns the latter years. Each section is a reciprocal counter to the
other. Importantly, Congress intended the sections to deal with "premarket
regulatory approval":
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The parties agree that the 1984 Act was designed to respond to two
    unintended
<span CLASS="page_no" data-cite="686 f 3d 1371" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1371" data-primary-citation="686 F.3d 1348">[*1371]</span> 
    distortions <span CLASS="page_no" data-cite="103 uspq 2d 1818" data-cite-type="ReporterOfDecisions" data-cite-pageno="1818" data-primary-citation="103 U.S.P.Q.2d 1800">[**1818]</span> of the 17-year patent term produced by the requirement
    that certain products must receive <b>premarket regulatory approval.</b>
    First, the holder of a patent relating to such products would as a
    practical matter not be able to reap any financial rewards during
    the early years of the term. . . . Thus, if the discovery relates to
    a product that cannot be marketed without substantial testing and
    regulatory approval, the "clock" on his patent term will be running
    even though he is not yet able to derive any profit from the
    invention. The second distortion occurred at the other end of the
    patent term. In 1984, the Court of Appeals for the Federal Circuit
    decided that the manufacture, use, or sale of a patented invention
    during the term of the patent constituted an act of infringement,
    see <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(a)</a>, even if it was for the sole purpose of conducting
    tests and developing information necessary <b>to apply for regulatory</b>
    <b>approval.</b><i>See <span CLASS="page_no" data-cite="2012 bl 196196 p 24" data-cite-type="Bloomberg" data-cite-pageno="24" data-primary-citation="">[***24]</span> Roche Products, Inc. v. Bolar Pharmaceutical Co.</i>,
    <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X3J5E7?jcsearch=733%20f%202d%20858&amp;summary=yes#jcite">733 F.2d 858</a> (Fed.Cir.1984). Since that activity could not be
    commenced by those who planned to compete with the patentee until
    expiration of the entire patent term, the patentee's de facto
    monopoly would continue for an often substantial period until
    regulatory approval was obtained. In other words, the combined
    effect of the patent law and the <b>premarket regulatory approval</b>
    requirement was to create an effective extension of the patent term.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. at 669-670</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a> (emphases added). Therefore:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      "The 1984 Act sought to eliminate this distortion from both ends
    of the patent period. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ032003?jcsearch=35%20U.S.C.%20%20201&amp;summary=yes#jcite">Section 201</a> of the Act established a
    patent-term extension for patents relating to certain products that
    were subject to lengthy regulatory delays and could not be marketed
    prior to regulatory approval. . . . Section 201 provides that
    patents relating to these products can be extended up to five years
    . . . The distortion at the other end of the patent period was
    addressed by <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">&sect; 202</a> of the Act. . . . This allows competitors, prior
    to the expiration of a patent, to engage in otherwise infringing
    activities necessary <b>to obtain regulatory approval."</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20U.S.%20661&amp;summary=yes#jcite">Id. at 670-71</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%22%20S.Ct.%202683&amp;summary=yes#jcite">110" S.Ct. 2683</a> (emphasis added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The 1984 Act enacted the two sections to create a balance. The Supreme
Court rejected the party's attempt to create a "disequilibrium" between the
two sections. <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20U.S.%20661&amp;summary=yes#jcite">Id. at 672</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court's new interpretation in this case would apply the disadvantage
of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">&sect; 202</a> to a patentee who would not be able to obtain the benefits of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ032003?jcsearch=35%20U.S.C.%20%20201&amp;summary=yes#jcite">&sect;
201</a>. The patentee of a manufacturing patent does not obtain the patent
extension created in <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ032003?jcsearch=35%20U.S.C.%20%20201&amp;summary=yes#jcite">&sect; 201</a>, yet this court's new expansion of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">&sect; 202</a> would
allow its competitors to infringe during the life of its patent. The Supreme
Court rejected this sort of disequilibrium. <i>See Proveris Scientific Corp. v.</i>
<i>Innovasystems, Inc.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X19B126003?jcsearch=536%20f%203d%201256&amp;summary=yes#jcite">536 F.3d 1256</a> (Fed.Cir.2008) (relying on <i>Merck</i> to hold
that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> does not apply to infringement of patented product not
eligible to obtain patent extension).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court's new interpretation does not reserve <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">&sect; 202</a> for the "end of the
patent term." Instead, its interpretation allows infringing activity
continuously throughout the life of the patent, including the "early years"
reserved for <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ032003?jcsearch=35%20U.S.C.%20%20201&amp;summary=yes#jcite">&sect; 201</a>. If, as the court claims, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">&sect; 202</a> was meant to cover the
continuous, commercial use throughout the
<span CLASS="page_no" data-cite="686 f 3d 1372" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1372" data-primary-citation="686 F.3d 1348">[*1372]</span> 
life of the patent, there would be no balance between <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ032003?jcsearch=35%20U.S.C.%20%20201&amp;summary=yes#jcite">&sect; 201</a> and <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ034003?jcsearch=35%20U.S.C.%20%20202&amp;summary=yes#jcite">&sect; 202</a>. This
decision improperly cuts short the life of Momenta's patent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  And, as already discussed, this new interpretation expands beyond
"premarket regulatory approval." <i>See</i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. at 669-670</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>. Its
interpretation allows infringing activity after the product has already been
approved for sale on the market.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Surprisingly, the court claims that its "analysis is not groundbreaking:
the Supreme Court came to essentially the same conclusion in 1990" and cites
<i>Eli Lilly.</i> Majority Op. 1355-56. It has been quoted that "Words are easy,
like the wind." Saying that something "is not ground-breaking" does not make
it so.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nowhere in <i>Eli Lilly</i> does the Supreme Court come to "essentially the same
conclusion" as the majority here. The Supreme Court does not say that the
mere maintenance <span CLASS="page_no" data-cite="2012 bl 196196 p 25" data-cite-type="Bloomberg" data-cite-pageno="25" data-primary-citation="">[***25]</span> or retention of records &mdash; with no intention to submit to
the FDA but that only could potentially be viewed by the FDA if the FDA
requested it &mdash; would satisfy as a "submission" to the FDA. The Supreme Court
does not sanction post-approval activity. The Supreme Court does not read
the word "solely" out from the statute.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is more telling what the court's reasoning omits than what it cites.
The court only relies <span CLASS="page_no" data-cite="103 uspq 2d 1819" data-cite-type="ReporterOfDecisions" data-cite-pageno="1819" data-primary-citation="103 U.S.P.Q.2d 1800">[**1819]</span> on a single sentence from <i>Eli Lilly</i>, which it quotes
out of context. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. at 666</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a> ("But the phrase `a Federal
law which regulates the manufacture, use, or sale of drugs' more naturally
summons up the image of an entire statutory scheme of regulation."). The
Supreme Court was not even referencing the same phrase that is at issue
here: "a Federal law," not "submission." In fact, that sentence is not even
in the section in the Supreme Court's opinion that discusses the basis on
which the Court decided the case. Instead, that sentence is in a prior
section discussing the text of the statute, which the Supreme Court found
"somewhat more naturally reads as the Court of Appeals determined, but that
is not plainly comprehensible on anyone's view." <i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20U.S.%20661&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The sentence cited by this court is not even a definitive holding of the
Supreme Court but instead a discussion of the parties' arguments. In looking
at the paragraphs following the one cited by this decision, the Supreme
Court states the case for the opposing side: "On the other side of the
ledger, however, one must admit that while the provision more naturally
means what respondent suggests, it is somewhat difficult to understand why
anyone would want it to mean that. Why should the touchstone of
noninfringement be whether the use is related to the development and
submission of information under a provision that happens to be included
within an Act that, in any of its provisions, not necessarily the one at
issue, regulates drugs?" <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=496%20U.S.%20661&amp;summary=yes#jcite">Id. at 668</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X5CBTS?jcsearch=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>. On other occasions, the
Federal Circuit advises against this type of slanted wordsmithing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Merck</i>, the Supreme Court addressed whether <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> applies to
research intended for submission for FDA approval but ultimately not
submitted to the FDA. <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. at 195</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a> ("This case presents
the question whether uses of patented inventions in preclinical research,
the results of which are not ultimately included in a submission to the Food
and Drug Administration (FDA), are exempted from infringement by 35 <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect;
271(e)(1)</a>.").
<span CLASS="page_no" data-cite="686 f 3d 1373" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1373" data-primary-citation="686 F.3d 1348">[*1373]</span> 
In other words, the case presented an instance of limited experiments
performed in the pre-approval stage of drug development.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nowhere does <i>Merck</i> suggest that post-approval, commercial, continuous
infringing use would be permitted. Indeed, <i>Merck</i> clearly lays out that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect;
271(e)(1)</a> is intended for pre-approval, experimental, limited use.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      "Basic scientific research on a particular compound, performed
    without the intent to develop a particular drug or a reasonable
    belief that the compound will cause the sort of physiological effect
    the researcher intends to induce, is surely not `reasonably related
    to the development and submission of information' to the FDA. It
    does not follow from this, however, that <span CLASS="page_no" data-cite="2012 bl 196196 p 26" data-cite-type="Bloomberg" data-cite-pageno="26" data-primary-citation="">[***26]</span> <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>'s exemption
    from infringement categorically excludes either (1) <b>experimentation</b>
    on drugs that are not ultimately the subject of an FDA submission or
    (2) use of patented compounds in <b>experiments</b> that are not ultimately
    submitted to the FDA. Under certain conditions, we think the
    exemption is sufficiently broad to protect the use of patented
    compounds in both situations." [<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. at 205-06</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>
    (emphasis added)] "Moreover, many of the uncertainties that exist
    with respect to <b>the selection of a specific drug</b> exist as well with
    respect to the decision of <b>what research to include</b> in an IND or
    NDA. As a District Court has observed, `[I]t will not always be
    clear to parties <b>setting out to seek FDA approval</b> for their new
    product exactly which kinds of information, and in what quantities,
    it will take <b>to win that agency's approval.'</b><i>Intermedics, Inc. v.</i>
    <i>Ventritex, Inc.</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X462DL?jcsearch=775%20f%20supp%201269&amp;summary=yes#jcite">775 F.Supp. 1269</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X462DL?jcsearch=775%20f%20supp%201269&amp;summary=yes#jcite">1280</a> (N.D.Cal.1991), aff d,
    <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X3BG3H1?jcsearch=991%20f%202d%20808&amp;summary=yes#jcite">991 F.2d 808</a> (Fed. Cir.1993). This is especially true at the
    preclinical stage of drug approval."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20us%20193&amp;summary=yes#jcite">545 U.S. at 207</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a> (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court relies on some text from <i>Merck</i> that appears superficially to
suggest an expansive interpretation of <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>. But, read in context,
that language has another meaning entirely. This language appears to suggest
that &sect; 271(e)(1) covers any sort of information or submission. But, this
language actually appears in the context of the issue in <i>Merck</i> of whether
information <i>intended</i> for submission to the FDA for approval should be
covered when the information was ultimately not submitted because the drug
candidate in that case lacked potential. This context is apparent in the
sentences <i>next to</i> the sentence quoted by the majority, which state:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      We decline to read the "reasonable relation" requirement so
    narrowly as to render <b><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(z)&amp;summary=yes#jcite">&sect; 271(e)(Z)</a>'s stated protection of activities</b>
    <b>leading to FDA approval</b> for all drugs illusory. Properly construed,
    <b><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> leaves <span CLASS="page_no" data-cite="103 uspq 2d 1820" data-cite-type="ReporterOfDecisions" data-cite-pageno="1820" data-primary-citation="103 U.S.P.Q.2d 1800">[**1820]</span> adequate space for experimentation and failure on</b>
    <b>the road to regulatory approval:</b> At least where a drug-maker has a
    reasonable basis for believing that a patented compound may work,
    through a particular biological process, to produce a particular
    physiological effect, and uses the compound in research that, if
    successful, would be appropriate to include in a submission to the
    FDA, that use is "reasonably related" to the "development and
    submission of information under . . . Federal law." <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">Id. at 207</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a> (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Merck</i> does not reduce the importance of the limitation that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> is
reserved
<span CLASS="page_no" data-cite="686 f 3d 1374" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1374" data-primary-citation="686 F.3d 1348">[*1374]</span> 
<b>"solely</b> for uses reasonably related to the development and submission of
information." Holding that preclinical research reasonably expected to
generate information for regulatory approval does not fall outside &sect;
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">271(e)(1)</a> simply because the research fails and does not result in a
regulatory application, <i></i><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=545%20U.S.%20193&amp;summary=yes#jcite">id. at 206-07</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X12DNQS003?jcsearch=125%20supreme%20court%202372&amp;summary=yes#jcite">125 S.Ct. 2372</a>, is a far cry from
permitting infringement during manufacture of a commercial product merely
because the infringing act also generates information that might someday be
submitted to the FDA, long after marketing approval is granted. Here,
Amphastar's use of the patented method is primarily for production of a
commercial <span CLASS="page_no" data-cite="2012 bl 196196 p 27" data-cite-type="Bloomberg" data-cite-pageno="27" data-primary-citation="">[***27]</span> product; it is not "solely for uses reasonably related to"
development of information.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As another point, this court claims that "the Court explicitly rejected
the notion that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> was limited `to the activities necessary to seek
approval of a generic drug.'" Majority Op. 1356. But, it is important to
understand what <i>Merck</i> was trying to distinguish. Read in context, that
phrase is referring to allowing <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> to include pre-<i>approval</i>
activities for a <i>branded drug.</i> It was <b>not</b> stating that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> included
post-<i>approval</i> activities for a <i>generic drug.</i> In other words, the Supreme
Court was emphasizing the words "generic drug," not the words "necessary to
seek approval." Imagine ordering a computer and stating that "I do not want
it delivered to my house on Wednesday." Then, the post office delivered it
to your neighbor's house on Thursday. Obviously, you meant to emphasize
"Wednesday," not "my house." Similarly, this court must read the Supreme
Court's cases as a whole and in context.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Just because <i>Merck</i> held that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> could cover pre-approval
activities for not only the ANDA but also the NDA and IND, does not mean
that the mere retention of documents as part of a company's records could be
considered a "submission" to the FDA. In other words, if a house owner
allows a hired painter to paint his house <i>any</i> and <i>all</i> shades of brown, that
is not permission to choose neon orange or turquoise.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Thus, while <i>Merck</i> said that as long as an activity was <i>intended</i> for
submission to obtain approval, then <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect; 271(e)(1)</a> applies even if the
information is not actually submitted (because it is difficult to predict
which drug candidates ultimately will be successful), it did not say that <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(1)&amp;summary=yes#jcite">&sect;
271(e)(1)</a> applies even if the activity was <i>never intended to obtain approval</i>
<i>at all.</i> Or if the information was <i>not even intended for submission to the</i>
<i>FDA.</i> This court's interpretation (that the mere retention of information as
part of a company's records can be a "submission" to the FDA) is indeed
"groundbreaking" and the Supreme Court did not "come to essentially the same
conclusion."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  V.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The safe harbor provision at issue in this case, due to its origin and
purpose in reversing <i>Roche v. Bolar</i>, receives attention as an exception that
permits experimentation. This link to experimentation and its role in
advancing the progress of technology requires some commentary as well. Too
often patent law is misunderstood as impeding more than promoting
innovation. This academic proposition, called the tragedy of the Anticommons
in some scholarly presentations, suggests that exclusive rights impede the
flow of information and limit experimentation that might lead to the next
generation of technological advance. Michael A. Heller &amp; Rebecca S.
<span CLASS="page_no" data-cite="686 f 3d 1375" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1375" data-primary-citation="686 F.3d 1348">[*1375]</span> 
Eisenberg, <i>Can Patents Deter Innovation? The Anticommons in Biomedical</i>
<i>Research</i>, 280 SCIENCE 698 (1998).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the first place, in an era of empirical research, one might ask the
reason that this academic notion has never actually been verified. Although
studied, no research has substantiated this alleged attack on the patent
system. In fact, "the effects predicted by the anticommons <span CLASS="page_no" data-cite="2012 bl 196196 p 28" data-cite-type="Bloomberg" data-cite-pageno="28" data-primary-citation="">[***28]</span> hypothesis are
not borne out in the available data." Timothy Caulfield, <i>Human Gene Patents:</i>
<i>Proof of Problems?</i>, 84 Chi.-Kent L.Rev. 133, 137 (2009); <i>see also</i> American
Association for the Advancement of Science, INTERNATIONAL INTELLECTUAL
PROPERTY EXPERIENCES: A REPORT OF FOUR COUNTRIES 12 (<span CLASS="page_no" data-cite="103 uspq 2d 1821" data-cite-type="ReporterOfDecisions" data-cite-pageno="1821" data-primary-citation="103 U.S.P.Q.2d 1800">[**1821]</span> 2007) (finding the
results of a 2006 survey of U.S. and Japanese researchers "offer very little
evidence of an `anticommons problem'" and that "IP-protected technologies
remain relatively accessible to the broad scientific community"). Surveys of
academic researchers have revealed that "only 1 percent . . . report having
to delay a project, and none abandoned a project due to others' patents."
Wesley M. Cohen &amp; John P. Walsh, <i>Real Impediments to Academic Biomedical Re</i>
<i>search, in</i> 8 INNOVATION POLICY AND THE ECONOMY 1, 10-11 (Adam B. Jaffe, Josh
Lerner, &amp; Scott Stern eds. 2008), <i>available at</i>
http://www.nber.org/marschke/mice/Papers/cohenwalsh.pdf (citing John P.
Walsh et al., <i>The View from the Bench: Patents, Material Transfers and</i>
<i>Biomedical Research</i>, 309 SCIENCE 2002 (2005)). In other words, patents on
research tools and biomedical innovations do not significantly slow the pace
of research and do not deter researchers from pursuing promising projects.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The reason that patents have not been proven to impede more than stimulate
technological advance is simple: it does not happen. It does not happen for
several reasons. First, experiments advancing technology rarely, if ever,
generate commercial value. Thus patent owners have little, if any, incentive
to license or inhibit research. Stated otherwise, even if a patent owner
wanted to sue or license potential researchers, experiments do not produce
income or a sources of damages. <i>See id.</i> at 12.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, in the modern age of technology, the character of technological
advance has changed. The era when the Bell Labs or some other tech center
could hire the most promising engineers and essentially invent everything
for the world has passed. With the vast specialization of all fields of
research, advances in technology require great cooperation. A new product or
a new direction in biotechnology or electronics will be produced by
cooperation between a professor in Chengdu, China, a young programmer in
Bangaluru, India, an engineer at a large corporation in Munich, Germany, a
graduate student at Tokyo University, and a team at a small start-up company
in Silicon Valley. The patent system can help inform each of them of the
other and bring together their incremental advances to achieve the next
generation of progress in some tiny corner of human progress.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Thus, patents properly remain a tool for research and experimentation
because the system encourages publication and sharing of research results.
Disclosure of how to make and use the invention is the "quid pro quo" of the
patent grant. <i>See JEM Ag Supply, Inc. v. Pioneer Hi-Bred Int'l, Inc.</i>,
<a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XAU2R6?jcsearch=534%20us%20124&amp;summary=yes#jcite">534 U.S. 124</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XAU2R6?jcsearch=534%20us%20124&amp;summary=yes#jcite">142</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XAU2R6?jcsearch=122%20supreme%20court%20593&amp;summary=yes#jcite">122 S.Ct. 593</a>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/XAU2R6?jcsearch=151%20l%20ed%202d%20508&amp;summary=yes#jcite">151 L.Ed.2d 508</a> (2001). In exchange for
disclosure, the inventor receives a limited term of exclusivity to benefit
from commercialization
<span CLASS="page_no" data-cite="686 f 3d 1376" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1376" data-primary-citation="686 F.3d 1348">[*1376]</span> 
of his invention. Without this promise of exclusivity, researchers at
corporations <span CLASS="page_no" data-cite="2012 bl 196196 p 29" data-cite-type="Bloomberg" data-cite-pageno="29" data-primary-citation="">[***29]</span> would be forced to turn to secrecy as the best protection for
their inventions. Even academic researchers may delay publication of results
in order to maintain an edge over the competition, Cohen &amp; Walsh, <i>supra</i> at
14, and the race to the patent office helps counteract this tendency toward
secrecy by rewarding earlier disclosure. "The information in patents is
added to the store of knowledge with the publication/issuance of the patent.
. . . [It] is not insulated from analysis, study, and experimentation for
the twenty years until patent expiration." <i>Classen</i>, <a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1G7FAI003?jcsearch=659%20f%203d%201057&amp;summary=yes#jcite">659 F.3d at 1072</a>.
Rather, information shared through patent applications is immediately
available for others to build upon. It speeds the progress of scientific
endeavor. In other words, the patent system's modern benefits facilitate
experimentation far more than any hypothetical inhibition.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  VI.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Every day, Amphastar, a competitor of Momenta, is infringing Momenta's
patent. This decision allows that trespass. Moreover, to reach that result,
this court must ignore its own prior decision in <i>Classen</i> and the purpose of
the statute explained in the legislative history. Sadly this decision
abrogates Momenta's hard-achieved property right and reallocates that
entitlement to its competitors &mdash; a sad day for property owners and an
undeserved victory for those who decline to invest in the expense and
difficulty of discovery and invention.
</p></div>
<!--BBLS DD 1720622252035-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I2EH8003/history">Direct History (14)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I2EH8003/analysis">Case Analysis (7)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I2EH8003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
6
</span>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/distinguished.png'>
<div class='citation distinguished icon printHide' title='Distinguished'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I2EH8003/analysis?analysis=distinguished'>
Distinguished
</a>
<span class='citationNumberLabel'>
1
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Vacated, Case Remanded</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceutical Manufacturing</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1Q6M2DJ0F82">12-01062 (Fed. Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1Q6M3AO6IO2">12-01103 (Fed. Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/9aca369ec3d150f388aba63c52579ed6/document/X1Q6M3AO75O2">12-01104 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Damages &amp; Remedies</div><div class='facetItemLabel'>Health Law</div><div class='facetItemLabel'>Patent Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/9aca369ec3d150f388aba63c52579ed6/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "9aca369ec3d150f388aba63c52579ed6";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY2dfe06&previousPageId=&previousActivityInstanceId=ENTITY84ed68&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:11:06-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1I2EH8003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY84ed68&previousPageId=&previousActivityInstanceId=ENTITY3648fa&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:11:00-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1I2EH8003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1I2EH8003";
$('#page_loader').show().spin();
JUDGE_IDS=["15753020","3027446","3408847"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
